Neutralizing antibodies against SARS-associated coronavirus
Novel monoclonal antibodies with targeted CDR sequences effectively neutralize SARS-CoV-2 variants and escape mutants, addressing the reduced efficacy of existing antibodies due to antigenic mutations.
Patent Information
- Application Number
- JP2024533080
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-16
- Filing Date
- 2022-12-01
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The emergence of SARS-CoV-2 variants with antigenic escape mutations has reduced the efficacy of existing neutralizing antibodies, posing a risk to unvaccinated individuals and immunocompromised patients, and there is a need for antibodies that retain potency against circulating and emerging variants.
Development of novel monoclonal antibodies with specific CDR sequences (R200-1B9, R207-2F11, R40-1G8, R568-2G5, etc.) that exhibit superior neutralizing potency against SARS-CoV-2 variants, including Omicron, by targeting conserved regions of the spike protein.
These antibodies demonstrate high neutralizing activity against multiple SARS-CoV-2 variants and escape mutants, providing effective treatment and prevention of COVID-19, even in the presence of antigenic escape mutations.
Smart Images

Figure 2024542793000004 
Figure 2024542793000005 
Figure 2024542793000006
Abstract
Description
[Technical field]
[0001] The present invention relates to antibodies or antigen-binding fragments thereof against SARS-associated coronavirus, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, kits comprising such antibodies or antigen-binding fragments thereof, and antibodies or antigen-binding fragments thereof and pharmaceutical compositions and kits for use as medicaments and in the treatment or prevention of disease caused by SARS-associated coronavirus. The present invention further relates to methods of treating, preventing or reducing the severity of infection with SARS-associated coronavirus, as well as nucleic acids encoding such antibodies or antigen-binding fragments thereof, expression vectors comprising such nucleic acids, host cells comprising such nucleic acids or expression vectors, and methods for making such antibodies or antigen-binding fragments thereof. [Background technology]
[0002] The COVID-19 pandemic has claimed more than four million lives worldwide over the past year and a half. Although the vast majority of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are mild, hospitalization and death can occur in all age groups, with older adults with comorbidities being particularly at risk. The rapid and successful development of an effective SARS-CoV-2 vaccine would be a critical breakthrough. A vaccine could prevent severe disease and death as well as reduce the spread of infection.
[0003] However, vulnerable populations such as unvaccinated individuals and immunocompromised patients unable to mount an adequate immune response remain susceptible to infection and severe complications. Moreover, the current rise in SARS-CoV-2 variants with antigenic escape mutations may reduce the efficacy of approved therapeutics and vaccines and increase the incidence of breakthrough infections. This justifies the need for interventions that can effectively treat SARS-CoV-2 infection by preventing severe disease and reducing morbidity.
[0004] Neutralizing antibodies (NAbs) are an important part of the humoral immune system to prevent and combat viral infections. They can block viral entry into cells and mediate the clearance of viral particles through Fc-mediated effector functions. Advanced single B cell cloning strategies have helped to elucidate the B cell response to SARS-CoV-2 and have led to the isolation of several potent monoclonal antibodies (mAbs) (Andreano, E. et al., (2021). Cell 184, 1821-1835 e1816; Ju, B. et al., (2020). Nature 584, 115-119; Kreer, C. et al., (2020). Cell 182, 843-854 e812; Liu, L. et al., (2020). Nature 584, 450-456; Robbiani, D. F. et al., (2020). Nature 584, 437-442; Rogers, T. F. et al., (2020). Science 369, 956-963; Zost, S. J. et al., (2020). Nat Med 26, 1422-1427.).
[0005] These SARS-CoV-2 antibodies are directed against the spike (S) protein expressed on the viral surface, which promotes viral entry into human cells by binding to the human ACE-2 receptor. On the spike protein, the majority of NAb responses are directed against the receptor-binding domain (RBD) or N-terminal domain (NTD) of the SARS-CoV-2 spike S1 domain. The S2 domain of the spike protein is more conserved than S1 among β-coronaviruses (β-CoVs), but mAbs targeting the S2 domain are rare and less potent (Pinto, D. et al., (2021). Science 373, 1109-1116; Sauer, MM et al., (2021). Nat Struct Mol Biol 28, 478-486.).
[0006] The extremely potent neutralizing capacity of RBD-directed antibodies has led to the clinical development of mAbs to treat and prevent COVID-19. Passive immunization with mAbs can not only prevent infection in exposed individuals, but also treat COVID-19 and prevent it from progressing to severe disease. Several of these mAbs have been cleared for use by FDA and EMA approval for the treatment of COVID-19 or are currently being investigated in phase III clinical trials.
[0007] Despite the success of antibody-mediated treatment of SARS-CoV-2 infection, the recent emergence of SARS-CoV-2 variants harboring antigenic escape mutations in the spike protein has reduced efficacy or rendered approved antibodies ineffective due to loss of neutralizing activity.
[0008] In particular, the SARS-CoV-2 omicron variant (lineage B.1.1.529) has recently emerged as a variant of concern that may pose additional and novel risks on a global scale. This variant displays an unusually large number of mutations, a significant number of which affect the spike protein that, at the time of the discovery of the omicron variant, is targeted by most COVID-19 vaccines and SARS-CoV-2 neutralizing monoclonal antibodies. This level of mutations has now led to concerns regarding its infectivity, immune system evasion, and vaccine resistance. Summary of the Invention
[0009] It is therefore essential to develop next-generation mAbs that retain potency and efficacy against circulating or emerging SARS-CoV-2 variants, including the novel omicron variant.
[0010] There remains a need for human antibodies against SARS-related coronaviruses that exhibit no autoreactivity and have superior neutralizing potency against circulating SARS-CoV-2 variants of concern and emerging escape variants compared to publicly available antibodies published in sufficient detail.
[0011] It is therefore an object of the present invention to provide novel monoclonal antibodies against SARS-associated coronavirus that do not exhibit autoreactivity and have good neutralizing potency against circulating SARS-CoV-2 variants of concern and emerging escape variants.It is a further object of the present invention to provide novel monoclonal antibodies against SARS-associated coronavirus that can be used to treat or prevent disease caused by SARS-associated coronavirus in human or animal subjects and to prevent infection of human or animal subjects with SARS-associated coronavirus.
[0012] Furthermore, it is an object of the present invention to provide novel monoclonal antibodies with excellent neutralizing potency against the recently identified SARS-CoV-2 omicron variant.
[0013] These objects have been solved by the aspects of the present invention defined hereinafter.
[0014] According to a first aspect of the present invention, there is provided an antibody or an antigen-binding fragment thereof against a SARS-associated coronavirus, the antibody or antigen-binding fragment being selected from the group consisting of R200-1B9 (having a CDR-H1 amino acid sequence of SEQ ID NO:27, a CDR-H2 amino acid sequence of SEQ ID NO:28, a CDR-H3 amino acid sequence of SEQ ID NO:29, a CDR-L1 amino acid sequence of SEQ ID NO:30, a CDR-L2 amino acid sequence of SEQ ID NO:31, and a CDR-L3 amino acid sequence of SEQ ID NO:32), R207-2F11 (having a CDR-H1 amino acid sequence of SEQ ID NO:33, a CDR-H2 amino acid sequence of SEQ ID NO:34, a CDR-H3 amino acid sequence of SEQ ID NO:35, and a CDR-L1 amino acid sequence of SEQ ID NO:36), R207-2F12 (having a CDR-H1 amino acid sequence of SEQ ID NO:37, a CDR-H2 amino acid sequence of SEQ ID NO:38, a CDR-H3 amino acid sequence of SEQ ID NO:39, a CDR-L1 amino acid sequence of SEQ ID NO:40, a CDR-L2 amino acid sequence of SEQ ID NO:41, and a CDR-L3 amino acid sequence of SEQ ID NO:42), R40-1G8 (having a CDR-H1 amino acid sequence of SEQ ID NO: 39, a CDR-H2 amino acid sequence of SEQ ID NO: 40, a CDR-H3 amino acid sequence of SEQ ID NO: 41, a CDR-L1 amino acid sequence of SEQ ID NO: 42, a CDR-L2 amino acid sequence of SEQ ID NO: 43, and a CDR-L3 amino acid sequence of SEQ ID NO: 44), R568-2G5 (having a CDR-H1 amino acid sequence of SEQ ID NO: 45, a CDR-H2 amino acid sequence of SEQ ID NO: 46, and a CDR-L3 amino acid sequence of SEQ ID NO: 47), R568-2B11 (having a CDR-H1 amino acid sequence of SEQ ID NO: 51, a CDR-H2 amino acid sequence of SEQ ID NO: 52, a CDR-H3 amino acid sequence of SEQ ID NO: 53, a CDR-L1 amino acid sequence of SEQ ID NO: 54, a CDR-L2 amino acid sequence of SEQ ID NO: 55, and a CDR-L3 amino acid sequence of SEQ ID NO: 56), R207-2G4 (having a CDR- H1 amino acid sequence, CDR-H2 amino acid sequence of SEQ ID NO:58, CDR-H3 amino acid sequence of SEQ ID NO:59, CDR-L1 amino acid sequence of SEQ ID NO:60, CDR-L2 amino acid sequence of SEQ ID NO:61, and CDR-L3 amino acid sequence of SEQ ID NO:62), R40-1C8 (having a CDR-H1 amino acid sequence of SEQ ID NO:63, a CDR-H2 amino acid sequence of SEQ ID NO:64, a CDR-H3 amino acid sequence of SEQ ID NO:65, a CDR-L1 amino acid sequence of SEQ ID NO:66, a CDR-L2 amino acid sequence of SEQ ID NO:67, and a CDR-L3 amino acid sequence of SEQ ID NO:68),R568-2B9 (having a CDR-H1 amino acid sequence of SEQ ID NO:69, a CDR-H2 amino acid sequence of SEQ ID NO:70, a CDR-H3 amino acid sequence of SEQ ID NO:71, a CDR-L1 amino acid sequence of SEQ ID NO:72, a CDR-L2 amino acid sequence of SEQ ID NO:73, and a CDR-L3 amino acid sequence of SEQ ID NO:74), R568-1B3 (having a CDR-H1 amino acid sequence of SEQ ID NO:75, a CDR-H2 amino acid sequence of SEQ ID NO:76, a CDR-H3 amino acid sequence of SEQ ID NO:77, and a CDR-L1 amino acid sequence of SEQ ID NO:78), R568-2E1 (having a CDR-H1 amino acid sequence of SEQ ID NO: 81, a CDR-H2 amino acid sequence of SEQ ID NO: 82, a CDR-H3 amino acid sequence of SEQ ID NO: 83, a CDR-L1 amino acid sequence of SEQ ID NO: 84, a CDR-L2 amino acid sequence of SEQ ID NO: 85, and a CDR-L3 amino acid sequence of SEQ ID NO: 86), R568-1G9 (having a CDR-H1 amino acid sequence of SEQ ID NO: 87, a CDR- R121-1F1 (having a CDR-H1 amino acid sequence of SEQ ID NO: 93, a CDR-H2 amino acid sequence of SEQ ID NO: 94, a CDR-H3 amino acid sequence of SEQ ID NO: 95, a CDR-L1 amino acid sequence of SEQ ID NO: 96, a CDR-L2 amino acid sequence of SEQ ID NO: 97, and a CDR-L3 amino acid sequence of SEQ ID NO: 98) and R259-1B9 (having the CDR-H1 amino acid sequence of SEQ ID NO: 99, the CDR-H2 amino acid sequence of SEQ ID NO: 100, the CDR-H3 amino acid sequence of SEQ ID NO: 101, the CDR-L1 amino acid sequence of SEQ ID NO: 102, the CDR-L2 amino acid sequence of SEQ ID NO: 103, and the CDR-L3 amino acid sequence of SEQ ID NO: 104).
[0015] In one embodiment of the first aspect of the invention, the antibody or antigen-binding fragment thereof is selected from the group consisting of R200-1B9 (having a variable region heavy chain amino acid sequence of SEQ ID NO: 1 and a variable region light chain amino acid sequence of SEQ ID NO: 2), R207-2F11 (having a variable region heavy chain amino acid sequence of SEQ ID NO: 3 and a variable region light chain amino acid sequence of SEQ ID NO: 4), R40-1G8 (having a variable region heavy chain amino acid sequence of SEQ ID NO: 5 and a variable region light chain amino acid sequence of SEQ ID NO: 6), R568-2G5 (having a variable region heavy chain amino acid sequence of SEQ ID NO: 7 and a variable region light chain amino acid sequence of SEQ ID NO: 8), R568-2B11 (having a variable region heavy chain amino acid sequence of SEQ ID NO: 9 and a variable region light chain amino acid sequence of SEQ ID NO: 10), R207-2G4 (having a variable region heavy chain amino acid sequence of SEQ ID NO: 11 and a variable region light chain amino acid sequence of SEQ ID NO: 12), R40-1C8 (having a variable region heavy chain amino acid sequence of SEQ ID NO: 13 and a variable region light chain amino acid sequence of SEQ ID NO: 14), R568-2G5 (having a variable region heavy chain amino acid sequence of SEQ ID NO: 7 and a variable region light chain amino acid sequence of SEQ ID NO: 8), R568-2B11 (having a variable region heavy chain amino acid sequence of SEQ ID NO: 9 and a variable region light chain amino acid sequence of SEQ ID NO: 10), R207-2G4 (having a variable region heavy chain amino acid sequence of SEQ ID NO: 11 and a variable region light chain amino acid sequence of SEQ ID NO: 12), R40-1C8 (having a variable region heavy chain amino acid sequence of SEQ ID NO: 1 and R259-1B9 (having a variable region heavy chain amino acid sequence of SEQ ID NO:25 and a variable region light chain amino acid sequence of SEQ ID NO:26).
[0016] According to one embodiment of the first aspect of the invention, the amino acid sequence comprised is of one antibody selected from the group comprising R200-1B9, R207-2F11, R40-1G8, R568-2G5, R568-2B11, R207-2G4, R40-1C8, R568-2B9 and R568-1B3, preferably one antibody from the group comprising R200-1B9, R207-2F11, R40-1G8 and R568-2G5.
[0017] According to another embodiment of the first aspect of the invention, the SARS-associated coronavirus strain is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
[0018] According to yet another embodiment of the first aspect of the invention, the amino acid sequences of the CDRs or the variable regions comprised in the antibody or antigen-binding fragment thereof are obtained from an antibody capable of neutralizing each of the SARS-CoV-2 strains B.1, B.1.1.7, B.1.351, B.1.429, B.1.617 and B.1.617.2 in a pseudovirus neutralization assay described in the description with an IC50 of at most 0.4 μg / ml, preferably at most 0.1 μg / ml, more preferably at most 0.05 μg / ml, even more preferably at most 0.025 μg / ml, even more preferably at most 0.01 μg / ml, even more preferably at most 0.0025 μg / ml, particularly preferably at most 0.0015 μg / ml.
[0019] According to yet another embodiment of the first aspect of the invention, the amino acid sequences of the CDRs or the variable regions comprised in the antibody or antigen-binding fragment thereof are obtained from an antibody capable of neutralizing each of the SARS-CoV-2 spike escape mutants 69-70del, K417E, N439K, K444Q, V445A, G446V, L452R, Y453F, L455F, G476S, S477N, E484K, F486V, F490S, Q493R, Q493K, S494P, N501Y in a pseudovirus neutralization assay described in the description with an IC50 of at most 1.3 μg / ml, preferably at most 0.5 μg / ml, more preferably at most 0.05 μg / ml, even more preferably at most 0.02 μg / ml, particularly preferably at most 0.01 μg / ml.
[0020] According to one embodiment of the first aspect of the invention, the amino acid sequences of the CDRs or the variable regions comprised in the antibody or antigen-binding fragment thereof are obtained from an antibody capable of neutralizing each of the emerging SARS-CoV-2 escape variants R346S, Q414H, N440K, and T478K in a pseudovirus neutralization assay described in the description with an IC50 of at most 0.0015 μg / ml.
[0021] According to yet another embodiment of the first aspect of the invention, the amino acid sequence of the variable region contained in the CDR or the antibody or antigen-binding fragment thereof is neutralized against SARS-CoV-2 variants in the pseudovirus neutralization assay described in the description across all variants and mutants with an average IC50 of at most 0.08 μg / ml, preferably at most 0.025 μg / ml, more preferably at most 0.01 μg / ml, even more preferably at most 0.006 μg / ml, particularly preferably at most 0.002 μg / ml. The antibodies are derived from antibodies capable of neutralizing SARS-CoV-2 variants Wu-01, B.1, B.1.1.7, B.1.351, B.1.429, B.1.617 and B.1.617.2, as well as SARS-CoV-2 escape mutants 69-70del, K417E, N439K, K444Q, V445A, G446V, L452R, Y453F, L455F, G476S, S477N, E484K, F486V, F490S, Q493R, Q493K, S494P, N501Y, R346S, Q414H, N440K, and T478K.
[0022] According to another embodiment of the invention, the antibody or antigen-binding fragment thereof does not exhibit autoreactivity defined as a detectable binding pattern when tested against permeabilized HEp-2 cells using an antinuclear antibody (ANA) test kit (NOVA-Lite HEp-2 ANA kit; Inova Diagnostics) at a concentration of 100 μg / ml of the antibody or antigen-binding fragment thereof.
[0023] According to a second aspect of the invention there is provided a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof according to the first aspect of the invention and at least one pharma- ceutically acceptable excipient.
[0024] According to an embodiment of the second aspect of the invention, the pharmaceutical composition is a vaccine composition for a human or animal subject.
[0025] According to a third aspect of the invention there is provided a kit comprising an antibody or antigen-binding fragment thereof according to the first aspect of the invention and a container.
[0026] According to a fourth aspect of the invention there is provided an antibody or antigen-binding fragment thereof according to the first aspect of the invention, a pharmaceutical composition according to the second aspect of the invention or a kit according to the third aspect of the invention for use as a medicament, preferably for use as a vaccine.
[0027] According to a fifth aspect of the invention, there is provided an antibody or antigen-binding fragment thereof according to the first aspect of the invention, a pharmaceutical composition according to the second aspect of the invention, or a kit according to the third aspect of the invention for use in the treatment or prevention of a disease caused by a SARS-related coronavirus in a human or animal subject, preferably for use in the treatment or prevention of a disease caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in a human or animal subject.
[0028] According to a sixth aspect of the invention, there is provided an antibody or antigen-binding fragment thereof according to the first aspect of the invention, a pharmaceutical composition according to the second aspect of the invention, or a kit according to the third aspect of the invention for use in preventing infection of a human or animal subject with a SARS-associated coronavirus, preferably infection of a human or animal subject with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2).
[0029] According to a seventh aspect of the invention there is provided a method of treating or preventing or reducing the severity of a SARS-associated coronavirus infection in a human and / or animal subject, the method comprising administering to said subject a therapeutically effective amount of at least one antibody and / or antigen-binding fragment thereof according to the first aspect of the invention.
[0030] According to an embodiment of the fourth or fifth or sixth or seventh aspect of the invention, the antibody is provided in combination with at least one further antibody against SARS-associated coronavirus 2 (SARS-CoV-2), said further antibody having a different binding specificity.
[0031] According to an embodiment of the fourth or fifth or sixth or seventh aspect of the invention the antibody is administered by intravenous infusion, subcutaneous injection, intramuscular injection or by inhalation application.
[0032] In one embodiment of the fourth or fifth or sixth or seventh aspect of the invention, the antibody or antigen-binding fragment of the invention is administered in an absolute dose of up to 4000 mg, preferably up to 2400 mg, more preferably up to 1200 mg, even more preferably up to 600 mg, even more preferably up to 300 mg, particularly preferably up to 150 mg.
[0033] According to an eighth aspect of the invention there is provided a nucleic acid encoding an antibody or antigen-binding fragment thereof according to the first aspect of the invention.
[0034] According to a ninth aspect of the invention there is provided an expression vector comprising a nucleic acid according to the eighth aspect of the invention in operative association with an expression control sequence.
[0035] According to a tenth aspect of the invention there is provided a host cell comprising a nucleic acid according to the eighth aspect of the invention or an expression vector according to the ninth aspect of the invention.
[0036] According to an eleventh aspect of the present invention there is provided a method of producing an antibody or antigen-binding fragment thereof according to the first aspect of the invention, the method comprising culturing a host cell according to the tenth aspect of the invention under conditions allowing expression of the antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment thereof. [Brief description of the drawings]
[0037] [Figure 1](A) Schematic of the study design used to identify and isolate monoclonal antibodies from SARS-CoV-2 elite neutralizers; (B) Heatmap showing serum or plasma IgG neutralizing IC50 values against SARS-CoV-2 Wu01 pseudovirus in the COVID-19 convalescent cohort studied (Vanshylla, K. et al., (2021). Cell Host Microbe 29, 917-929). Pie chart shows the percentage of elite neutralizers in the cohort (3.3%). [Diagram 2] Figure 1 shows the neutralization profiles of the elite neutralizer NAbs of the present invention (top panel) and reference antibodies (bottom panel) against 25 SARS-CoV-2 spike pseudovirus variants. The mean IC50 values and relative neutralization breadth across variants, as well as IGHV3-53 usage, are shown in the right column. Cross-neutralizing antibodies R121-3G2 and R40-1E1 with neutralizing activity against SARS-CoV-1 and bat-CoV WIV-1 pseudoviruses are shown in the middle panel. [Diagram 3] Figure 1 shows a plot showing IC50 values of the broadest (100%) and most potent elite Nabs of the invention against SARS-CoV-2 pseudovirus variants with spike sequences of circulating variants B.1, B.1.1.7, B.1.351, B.1.429, B.1.617 and B.1.617.2 compared to published monoclonal reference antibodies, including antibodies approved for clinical use. The grey area highlights values below 0.02 μg / ml and the line indicates the geometric mean IC50 value across all variants. [Figure 4] FIG. 1 shows neutralization analysis of the 13 most potent and broad-spectrum bNAbs of the invention along with published antibodies tested against SARS-CoV-2 pseudoviruses harboring one of the four emerging spike mutations, R346S, Q414H, N440K and T478K. [Diagram 5] A schematic diagram of the SARS-COV-2 spike domain highlighting the mutated residues in the VOCs or VOIs used in the study is shown. [Figure 6A]Figure 1 shows individual values of neutralization potency of the 13 most potent and broad spectrum bNAbs of the invention, as well as the cross-neutralizing antibodies R121-3G2 and R40-1E1 of the invention, along with the published antibodies tested, against true virus isolates (shown as IC100 in μg / ml), and against the 25 SARS-CoV-2 spike pseudovirus variants shown in Figure 2, and against SRAS-CoV-2 pseudoviruses with one of the four emerging spike mutations, R346S, Q414H, N440K and T478K, shown in Figure 4. The average neutralization potency across all 25 SARS-CoV-2 pseudovirus variants tested, as well as the neutralization potency against SARS-CoV-1 pseudoviruses and WIV-1 (bat coronavirus) pseudoviruses, are also shown. [Figure 6B] Same as above. [Figure 6C] Same as above. [Figure 6D] Same as above. [Figure 7] Figure 1 shows individual values for the neutralization potency of the 13 most potent and broad spectrum bNAbs of the invention, as well as the cross-neutralizing antibodies R121-3G2 and R40-1E1 of the invention, along with the published antibodies tested, against the SARS-CoV-2 spike quasi-variant harboring the spike protein mutation identified in the BA.1 lineage of the Omicron variant (shown as IC50 in μg / ml). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0038] In order that this description may be more readily understood, certain terms are first defined. Further definitions are provided throughout the detailed description.
[0039] It should be noted that the term "a" or "an" entity refers to one or more of that entity; for example, a "nucleotide sequence" is understood to represent one or more nucleotide sequences. Thus, the terms "a" (or "an"), "one or more," and "at least one" may be used interchangeably herein.
[0040] Furthermore, "and / or" as used herein is considered to be a specific disclosure of each of the two specified features or components, whether or not the other is present. Thus, when used in phrases such as "A and / or B" herein, the term "and / or" is intended to include "A and B," "A or B," "A" (single), and "B" (single). Similarly, when used in phrases such as "A, B, and / or C," the term "and / or" is intended to include each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (single); B (single); and C (single).
[0041] Whenever an embodiment is described herein with the language "comprising," it is understood that other similar embodiments described with the terms "consisting of" and / or "consisting essentially of" are also provided.
[0042] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure pertains.For example, Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press provide those skilled in the art with a general dictionary of many terms used in this disclosure.
[0043] Units, prefixes, and symbols are expressed in their International System of Units (SI) accepted format. Numeric ranges are inclusive of the numbers defining the range. Nucleotide sequences are written left to right in 5' to 3' orientation unless otherwise indicated. Amino acid sequences are written left to right in amino to carboxy orientation. The headings provided herein are not intended to limit the various aspects of the disclosure, which may be had by reference to the specification in its entirety. Thus, the terms defined immediately below are more fully defined by reference to the specification in its entirety.
[0044] The term "about" is used herein to mean approximately, roughly, in the vicinity of, or in the region of. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" can modify numerical values above and below the stated value by, for example, a variance of up to or below 10 percent (higher or lower).
[0045] As used herein, the term "antibody" is used in the broadest sense to refer to molecules having immunoglobulin-like domains (e.g., IgG, IgM, IgA, IgD or IgE) and includes monoclonal, recombinant, polyclonal, chimeric, human, humanized, multispecific antibodies, including bispecific antibodies, and heteroconjugate antibodies; single variable domains (e.g., V H , V HH , V L , domain antibodies), antigen-binding antibody fragments, Fab, F(ab')2, Fv, disulfide-linked Fv, single chain Fv, disulfide-linked scFv, diabodies, and the like, including modified forms of any of the foregoing.
[0046] As used herein, the term "antibody" refers to a protein derived from a germline immunoglobulin sequence and capable of specifically binding to an antigen or an antigen-binding portion thereof. The term includes full-length antibodies of any class or isotype (i.e., IgA, IgD, IgE, IgG, IgM and / or IgY), and any single chain or fragment thereof. An antibody that specifically binds to an antigen or its antigen-binding portion may bind only to that antigen or portion thereof, or it may bind to a limited number of homologous antigens or portions thereof. A full-length antibody usually comprises at least four polypeptide chains: two heavy (H) chains and two light (L) chains that are interconnected by disulfide bonds.
[0047] One immunoglobulin subclass of particular pharmaceutical interest is the IgG family. In humans, the IgG class can be subdivided into four subclasses based on the sequences of their heavy chain constant regions: IgG1, IgG2, IgG3 and IgG4. Light chains can be divided into two types, kappa and lambda, based on differences in their sequence composition. An IgG molecule is composed of two heavy chains linked by two or more disulfide bonds, and two light chains, each linked to a heavy chain by a disulfide bond. The heavy chains can include a heavy chain variable region (VH) and up to three heavy chain constant (CH) regions: CH1, CH2 and CH3. The light chains can include a light chain variable region (VL) and a light chain constant region (CL).
[0048] The VH and VL regions can be further subdivided into regions of hypervariability, called complementarity determining regions (CDRs), interspersed with more conserved regions, called framework regions (FRs). The VH and VL regions are typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The hypervariable regions of the heavy and light chains form a binding domain that can interact with an antigen, while the constant regions of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including, but not limited to, various cells of the immune system (effector cells), Fc receptors, and the first component (C1q) of the classical complement system. The antibody of the present invention may be isolated.
[0049] The term "isolated antibody" refers to an antibody that has been separated and / or recovered from (other) components in the environment in which it is produced and / or purified from a mixture of components present in the environment in which it is produced. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody, so certain antigen-binding fragments of antibodies may be suitable in the context of the present invention.
[0050] The terms "antigen-binding portion," "binding fragment," or "antigen-binding fragment" of an antibody, as described herein, refer to one or more fragments of an antibody that retain the ability to specifically bind to an antigen, such as the spike (S) protein of SARS-CoV-2.
[0051] Examples of antigen-binding fragments include Fab, Fab', F(ab)2, F(ab')2, F(ab)S, Fv (typically the VL and VH domains of a single arm of an antibody), single-chain Fv (scFv; see, e.g., Bird et al., Science 242:42S-426 (1988); Huston et al., PNAS 85:5879-5883 (1988)), dsFv, Fd (typically the VH and CH1 domains), and dAb (typically the VL and CH1 domains). HDomain) fragment;V H , V L , V HH , and V-NAR domains; a single V H Chain and single V L These include monovalent molecules comprising a chain; minibodies, diabodies, triabodies, tetrabodies, and kappabodies (see, e.g., Ill et al., Protein Eng 10:949-57 (1997)); camelid IgG; IgNAR; and one or more isolated CDRs or functional paratopes, which isolated CDRs or antigen-binding residues or polypeptides may be associated or linked together to form a functional antibody fragment.
[0052] Various types of antibody fragments are described or reviewed, for example, in Holliger and Hudson, Nat Biotechnol 2S:1126-1136 (2005); International Publication No. WO2005 / 040219, and U.S. Publication Nos. 2005 / 0238646 and 2002 / 0161201. These antibody fragments can be obtained using conventional techniques known to those of skill in the art, and the fragments can be screened for utility in the same manner as intact antibodies.
[0053] A "human" antibody (HuMAb) refers to an antibody having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Additionally, if the antibody contains a constant region, the constant region is also derived from human germline immunoglobulin sequences. The SARS-CoV-2 antibodies described herein can include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, as used herein, the term "human antibody" is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences. The terms "human" antibody and "fully human" antibody are used interchangeably.
[0054] A "humanized" antibody refers to a human / non-human chimeric antibody that contains one or more sequences (CDR regions or parts thereof) derived from a non-human immunoglobulin. Thus, a humanized antibody is a human immunoglobulin (recipient antibody) in which at least residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of an antibody (donor antibody) derived from a non-human species, such as from mouse, rat, rabbit or non-human primate, having the desired specificity, affinity, sequence composition and functionality. In some cases, FR residues of the human immunoglobulin are replaced by the corresponding non-human residues. An example of such a modification is the introduction of one or more so-called back mutations, which are typically amino acid residues derived from the donor antibody.
[0055] Antibody humanization can be performed using recombinant techniques known to those skilled in the art (see, for example, Antibody Engineering, Methods in Molecular Biology, vol. 248, edited by Benny KC Lo). Suitable human recipient frameworks for both light and heavy chain variable domains can be identified, for example, by sequence or structural homology. Alternatively, fixed recipient frameworks can be used, for example, based on knowledge of structure, biophysical and biochemical properties. Recipient frameworks can be derived from germline or from mature antibody sequences. CDR regions from donor antibodies can be transferred by CDR grafting.
[0056] CDR-grafted humanized antibodies can be further optimized, for example, for affinity, functionality and biophysical properties, by identification of key framework positions where reintroduction of amino acid residues from the donor antibody (backmutation) beneficially affects the properties of the humanized antibody. In addition to backmutations from the donor antibody, humanized antibodies can be engineered by introduction of germline residues in the CDR or framework regions, removal of immunogenic epitopes, site-directed mutagenesis, affinity maturation, etc.
[0057] Furthermore, humanized antibodies can contain residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further improve antibody performance. In general, a humanized antibody contains at least one, and typically two, variable domains, with all or substantially all of the CDR regions corresponding to those of a non-human immunoglobulin and all or substantially all of the FR residues being those of a human immunoglobulin sequence. A humanized antibody can also contain at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. The term "humanized antibody derivatives" refers to modified forms of humanized antibodies, such as antibodies and conjugates of other agents or antibodies.
[0058] As used herein, the term "recombinant human antibody" includes all human antibodies that are prepared, expressed, produced or isolated by recombinant means, such as (a) antibodies isolated from animals (e.g., mice) that are transgenic or transchromosomal for human immunoglobulin genes, or hybridomas prepared therefrom; (b) antibodies isolated from host cells, e.g., transfectomas, that have been transformed to express the antibody; (c) antibodies isolated from recombinant, combinatorial human antibody libraries; and (d) antibodies prepared, expressed, produced or isolated by any other means involving splicing of human immunoglobulin gene sequences into other DNA sequences.
[0059] Such recombinant human antibodies include variable and constant regions that utilize specific human germline immunoglobulin sequences encoded by germline genes, but with subsequent rearrangements and mutations that occur, for example, during antibody maturation. As known in the art (see, e.g., Lonberg Nature Biotech. 23(9):1117-1125 (2005)), the variable regions include antigen-binding domains, which are encoded by various genes that rearrange to form antibodies specific to foreign antigens. In addition to rearrangements, the variable regions can be further modified by multiple single amino acid changes (referred to as somatic mutations or hypermutations) to increase the affinity of the antibody for the foreign antigen. The constant regions further change in response to antigen (i.e., isotype switching).
[0060] Thus, the rearranged and somatically mutated nucleic acid molecules that encode light and heavy chain immunoglobulin polypeptides in response to an antigen may not have sequence identity to the original nucleic acid molecule, but instead will be substantially identical or similar (i.e., have at least 80% identity).
[0061] A "chimeric antibody" refers to an antibody whose variable region derives from one species and whose constant region derives from another species, e.g., the variable region derives from a murine antibody and the constant region derives from a human antibody.
[0062] Alternative antibody formats include alternative scaffolds in which one or more CDRs of the antigen-binding moiety can be placed onto a suitable non-immunoglobulin protein scaffold or framework, such as an affibody, an SpA scaffold, an LDL receptor class A domain, an avimer or an EGF domain.
[0063] The term "domain" refers to a folded protein structure that retains its tertiary structure independent of the rest of the protein. Generally, domains are responsible for distinct functional properties of the protein and can often be added, removed, or transferred to other proteins without loss of function of the rest of the protein and / or the domain.
[0064] The term "single variable domain" refers to a folded polypeptide domain that contains a sequence characteristic of an antibody variable domain. H , V HH and V L As well as modified antibody variable domains, for example in which one or more loops have been replaced by sequences not characteristic of antibody variable domains, or antibody variable domains which have been truncated or which contain N- or C-terminal extensions, as well as folded fragments of variable domains which retain at least the binding activity and specificity of the full-length domain.
[0065] A single variable domain can bind to an antigen or epitope independently of a different variable region or domain. A "domain antibody" or "dAb™" can be considered the same as a "single variable domain." Single variable domains can be human single variable domains, but also include V domains from rodents, nurse sharks and camelids. HH It also includes single variable domains from other species, such as dAbs™. HH V is an immunoglobulin single variable domain polypeptide derived from species including camel, llama, alpaca, dromedary, and guanaco, which produce heavy chain antibodies that are naturally devoid of light chains. HH A domain can be humanized according to standard techniques available in the art, and such a domain is considered to be a "single variable domain." As used herein, V H V is a member of the Camelidae family. HH Includes the domain.
[0066] An antigen-binding fragment may be provided by the arrangement of one or more CDRs on a non-antibody protein scaffold. As used herein, "protein scaffold" includes, but is not limited to, an immunoglobulin (Ig) scaffold, such as an IgG scaffold, which may be a four-chain or two-chain antibody, or may include only the Fc region of an antibody, or may include one or more constant regions from an antibody, which may be of human or primate origin, or may be an artificial chimera of human and primate constant regions.
[0067] As used herein, "isotype" refers to the antibody class (e.g., IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, and IgE antibodies) that is encoded by heavy chain constant region genes.
[0068] "Allotype" refers to naturally occurring variants within a particular isotype group, which variants differ by a few amino acids (see Jefferis et al., mAbs 1:1 (2009)).
[0069] The phrases "an antibody that recognizes an antigen" and "an antibody specific for an antigen" are used interchangeably herein with the term "an antibody that specifically binds to an antigen."
[0070] The terms "treat", "treating", or "treatment of" (or grammatical equivalents) mean that the severity of a subject's condition is reduced or at least partially ameliorated or improved, and / or some alleviation, reduction or diminution is achieved in at least one clinical symptom, and / or the progression of the condition is slowed.
[0071] As used herein, the terms "prevent", "prevents", or "prevention", and "inhibit", "inhibits", or "inhibition" (and their grammatical equivalents) are not meant to indicate complete elimination of a disease, but rather encompass any type of prophylactic treatment that reduces the occurrence of a condition, delays the onset of a condition, and / or reduces symptoms associated with a condition after onset.
[0072] As used herein, an "effective", "prophylactically effective" or "therapeutically effective" amount is an amount sufficient to bring about some degree of improvement or benefit to a subject. In other words, an "effective", "prophylactically effective" or "therapeutically effective" amount is an amount that brings about some degree of delay, relief, alleviation or reduction in at least one clinical symptom in a subject. Those skilled in the art will understand that the effect does not have to be complete or curative, as long as some degree of benefit is brought about to the subject.
[0073] As used herein, a "neutralizing antibody" is any antibody or antigen-binding fragment thereof that binds to a pathogen and prevents the pathogen's ability to infect cells and / or cause disease in a subject.
[0074] "Peptide" as used herein includes peptides that are conservative mutations of the peptides specifically exemplified herein. "Conservative mutation" and "conservative amino acid substitution" as used herein refer to the replacement of an amino acid residue with another biologically similar residue. Examples of conservative mutations include, but are not limited to, the replacement of one hydrophobic residue with another, such as isoleucine, valine, leucine, alanine, cysteine, glycine, phenylalanine, proline, tryptophan, tyrosine, norleucine or methionine, or the replacement of one polar residue with another, such as the replacement of arginine with lysine, the replacement of glutamic acid with aspartic acid, or the replacement of glutamine with asparagine. Neutral hydrophilic amino acids that can be substituted for each other include asparagine, glutamine, serine and threonine.
[0075] "Conservative mutation" also includes the use of a substituted amino acid in place of the unsubstituted parent amino acid, provided that the antibodies raised against the substituted polypeptide also immunoreact with the unsubstituted polypeptide. Such conservative substitutions are within the definition of the class of peptides of the present invention. The biological activity of a peptide can be determined by standard methods known to those skilled in the art and described herein.
[0076] With respect to nucleic acids, the term "substantial homology" indicates that two nucleic acids, or designated sequences thereof, when optimally aligned and compared are identical in at least about 80%, at least about 90%-95%, or at least about 98%-99.5% of the nucleotides, with appropriate nucleotide insertions or deletions. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization conditions, to the complement of the strand.
[0077] With respect to polypeptides, the term "substantial homology" indicates that two polypeptides, or designated sequences thereof, when optimally aligned and compared, are identical in at least about 80%, at least about 90%-95%, or at least about 98%-99.5% of the amino acids, with appropriate amino acid insertions or deletions.
[0078] The percent identity between two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps that need to be introduced for optimal alignment of the two sequences and the length of each gap (i.e., % homology = number of identical positions / total number of positions x 100). The comparison of sequences and determination of the percent identity between two sequences can be accomplished using a mathematical algorithm, as described in the non-limiting examples below.
[0079] Nucleic acid can be present in whole cells, in cell lysates, or in partially purified or substantially pure form. Nucleic acid is "isolated" or "substantially pure" when it is purified away from other cellular components or other contaminants, such as other cellular nucleic acids (e.g., other parts of chromosomes) or proteins, by standard techniques, including alkaline / SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis, and others well known in the art. See F. Ausubel et al., ed. Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York (1987).
[0080] Nucleic acid, for example, cDNA, can be mutated according to standard techniques to provide gene sequences. For coding sequences, these mutations can affect the desired amino acid sequence. In particular, DNA sequences that are substantially homologous to or derived from natural V, D, J, constant, switch and other such sequences described herein are contemplated (wherein "derived" indicates that the sequence is identical to or modified from another sequence).
[0081] The term "vector" as used herein is intended to refer to a nucleic acid molecule that can transport another nucleic acid to which it is linked. One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, into which additional DNA or RNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in the host cell into which they are introduced (e.g., bacterial vectors with a bacterial origin of replication and episomal mammalian vectors).
[0082] Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell when introduced into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors"). In general, expression vectors useful in recombinant DNA techniques are often in the form of plasmids. As used herein, "plasmid" and "vector" can be used interchangeably, as plasmids are the most commonly used form of vector. However, other forms of expression vectors, such as viral vectors (e.g., replication-defective retroviruses, adenoviruses and adeno-associated viruses), are also included, which serve equivalent functions.
[0083] The term "recombinant host cell" (or simply "host cell") as used herein is intended to refer to a cell that contains a nucleic acid that does not naturally occur in the cell, and may be a cell into which a recombinant expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell, but also to the progeny of such a cell. Because certain modifications may occur in subsequent generations, either due to mutation or environmental influences, such progeny may not in fact be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.
[0084] The term "linked" as used herein refers to the association of two or more molecules. The linkage may be covalent or non-covalent. The linkage may also be genetic (i.e., recombinantly fused). Such linkages may be achieved using a variety of art-recognized techniques, such as chemical conjugation and recombinant protein production.
[0085] "Effector function" refers to the interaction of antibody Fc region with Fc receptor or ligand, or the biochemical events resulting therefrom. Exemplary "effector functions" include C1q binding, complement-dependent cytotoxicity (CDC), Fc receptor binding, FcγR-mediated effector functions such as ADCC and antibody-dependent cell-mediated phagocytosis (ADCP), and down-regulation of cell surface receptors (e.g., B cell receptor; BCR). Such effector functions generally require the Fc region to be combined with a binding domain (e.g., an antibody variable domain).
[0086] An "Fc receptor" or "FcR" is a receptor that binds to the Fc region of an immunoglobulin. FcRs that bind IgG antibodies include the FcγR family of receptors, including allelic variants and alternatively spliced forms of these receptors. The FcγR family consists of three activating (FcγRI, FcγRIII, and Fc.RIV in mice; FcγRIA, FcγRIIA, and FcγRIIIA in humans) and one inhibitory (FcγRIIB) receptor. The various properties of human FcγRs are known in the art. The majority of innate effector cell types co-express one or more activating FcγRs and inhibitory FcγRIIB, whereas natural killer (NK) cells selectively express one activating Fc receptor (FcγRIII in mice, and FcγRIIIA in humans) but do not express inhibitory FcγRIIB in mice and humans. Human IgG1 binds to most human Fc receptors and is considered equivalent to mouse IgG2a with respect to the types of activating Fc receptors it binds.
[0087] "Fc region" (Fragment crystallizable region) or "Fc domain" or "Fc" refers to the C-terminal region of the heavy chain of an antibody that mediates binding of immunoglobulins to host tissues or factors, including binding to Fc receptors present on various cells of the immune system (e.g., effector cells) or binding to the first component (C1q) of the classical complement system. Thus, the Fc region includes the constant region of an antibody excluding the first constant region immunoglobulin domain (e.g., CH1 or CL).
[0088] A "native sequence Fc region" or "native sequence Fc" comprises an amino acid sequence identical to the amino acid sequence of an Fc region found in nature. Native sequence human Fc regions include native sequence human IgG1 Fc region; native sequence human IgG2 Fc region; native sequence human IgG3 Fc region; and native sequence human IgG4 Fc region, as well as naturally occurring variants thereof. Native sequence Fc includes various allotypes of Fc (see, e.g., Jefferis et al., mAbs 1:1 (2009)).
[0089] A "variant sequence Fc region" or "non-naturally occurring Fc" typically contains modifications to alter one or more of its functional properties, such as, inter alia, serum half-life, complement binding, Fc receptor binding, protein stability and / or antigen-dependent cellular cytotoxicity, or lack thereof. In some embodiments, an antibody of the present disclosure may be chemically modified (e.g., one or more chemical moieties may be attached to the antibody) or modified to alter its glycosylation and to alter one or more functional properties of the antibody.
[0090] The terms "hinge", "hinge domain", "hinge region" and "antibody hinge region" refer to the domain of the heavy chain constant region that connects the CH1 domain to the CH2 domain, including the upper, middle and lower parts of the hinge (Roux et al., J Immunol 161:4083 (1998)). The hinge provides varying levels of flexibility between the binding and effector regions of the antibody, and also provides a site for intermolecular disulfide bonds between the two heavy chain constant regions. The sequences of wild-type IgG1, IgG2, IgG3 and IgG4 hinges are known in the art (e.g., International PCT Publication No. WO2017 / 087678). In one embodiment, the hinge region of CH1 of the antibody is modified to change, e.g., increase or decrease, the number of cysteine residues in the hinge region. This approach is further described, e.g., in U.S. Pat. No. 5,677,425.
[0091] The constant region may be modified to stabilize the antibody, for example to reduce the risk of a bivalent antibody separating into two monovalent VH-VL fragments. For example, in the IgG4 constant region, residue S228 (residue numbering according to the EU index) may be mutated to a proline (P) residue to stabilize inter-heavy chain disulfide bridge formation at the hinge (see, for example, Angal et al., Mol Immunol. 30:105-8 (1995)). Antibodies or fragments thereof may also be defined in terms of their complementarity determining regions (CDRs).
[0092] The term "complementarity determining region" or "hypervariable region" as used herein refers to the region of an antibody in which the amino acid residues involved in antigen binding are located. The hypervariable region or CDR can be identified as the region with the highest variability in the amino acid alignment of the antibody variable domain. Databases such as the Kabat database can be used for CDR identification, where CDRs are defined to include, for example, amino acid residues 24-34 (CDR1), 50-59 (CDR2) and 89-97 (CDR3) in the light chain variable domain, and amino acid residues 31-35 (CDR1), 50-65 (CDR2) and 95-102 (CDR3) in the heavy chain variable domain; (Kabat et al., 1991; Sequences of Proteins of Immunological Interest, Fifth Edition, USDepartment of Health and Human Services, NIH Publication No. 91-3242). Alternatively, the CDRs can be defined as residues from the "hypervariable loops" (residues 26-33 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable domain, and residues 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chain variable domain (Chothia and Lesk, J. Mol. Biol 196:901-917 (1987)). The CDR regions of the antibody sequences described herein are preferably defined according to the IMGT numbering scheme, which is an adaptation of the Chothia numbering scheme (ImMunoGeneTics information system™; Lefranc, M.-P. et al., IMGT, International ImMunoGeneTics Database, Nucleic Acids Res 27, 209-212 (1999); http: / / imgt.org).
[0093] The term "epitope" or "antigenic determinant" refers to a site on an antigen to which an immunoglobulin or antibody specifically binds, defined, for example, by the particular method used to identify it. Epitopes can be formed both from contiguous amino acids (usually linear epitopes) or from non-contiguous amino acids juxtaposed by tertiary folding of a protein (usually conformational epitopes). Epitopes formed from contiguous amino acids are typically, but not necessarily, retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents.
[0094] An epitope typically comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in a unique spatial conformation. Methods for determining which epitopes bind to a given antibody (i.e., epitope mapping) are well known in the art and include, for example, immunoblotting and immunoprecipitation assays, in which overlapping or consecutive peptides (e.g., from the spike (S) protein of SARS-CoV-2) are tested for reactivity with a given antibody. Methods for determining the spatial conformation of an epitope include techniques in the art, such as X-ray crystallography, antigenic mutation analysis, two-dimensional nuclear magnetic resonance, and HDX-MS (see, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, GE Morris, Ed. (1996)).
[0095] The term "binds to the same epitope" in reference to two or more antibodies means that the antibodies bind to the same segment of amino acid residues as determined by a given method. Techniques for determining whether an antibody binds to the "same epitope" as an antibody described herein include, for example, epitope mapping methods, such as X-ray analysis of crystals of antigen:antibody complexes that provide atomic resolution of the epitope, and hydrogen / deuterium exchange mass spectrometry (HDX-MS).
[0096] Other methods monitor the binding of antibodies to antigen fragments or mutated variations of the antigen, where loss of binding due to modification of amino acid residues within the antigen sequence is often taken as an indication of epitope components. Additionally, computational combinatorial methods for epitope mapping can also be used. These methods rely on the ability of the antibody of interest to affinity isolate specific short peptides from combinatorial phage display peptide libraries. The same V H and V L Alternatively, antibodies with the same CDR1, 2 and 3 sequences are predicted to bind to the same epitope.
[0097] An antibody that "competes with another antibody for binding to a target" refers to an antibody that inhibits (partially or completely) the binding of that other antibody to a target. Whether two antibodies compete with each other for binding to a target, i.e., whether and to what extent one antibody inhibits the binding of the other antibody to a target, can be determined using known competition experiments, for example, BIACORE™ surface plasmon resonance (SPR) analysis. In certain embodiments, an antibody competes with another antibody for binding to a target by at least 50%, 60%, 70%, 80%, 90% or 100% and inhibits the binding of the other antibody to the target. The level of inhibition or competition can vary depending on which antibody is the "blocking antibody" (i.e., the cold antibody that is first incubated with the target).
[0098] Competitive assays can be performed, for example, as described in Ed Harlow and David Lane, Cold Spring Harb Protoc; 2006; doi:10.1101 / pdb.prot4277 or Chapter 11 of "Using Antibodies" by Ed Harlow and David Lane, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA 1999. Two antibodies "cross-compete" when they block each other by at least 50% in both ways, i.e., regardless of whether one antibody or the other is the first to contact the antigen in a competition experiment.
[0099] As used herein, the terms "specific binding," "selective binding," "selectively binds," and "specifically binds" refer to an antibody binding to an epitope on a given antigen. Preferably, an antibody binds to a given antigen with an affinity that is at least two-fold greater than the affinity it binds to a non-specific antigen other than the given antigen or a closely related antigen (e.g., BSA, casein).
[0100] As used herein, the term "binding affinity" refers to a measure of the strength of a non-covalent interaction between two molecules, such as an antibody or fragment thereof and an antigen. The term "binding affinity" is used to indicate a monovalent interaction (intrinsic activity). The binding affinity between two molecules, for example, an antibody or fragment thereof and an antigen, via monovalent interactions is determined by the equilibrium dissociation constant (K D ) can be quantified by determining K D can be determined by measuring the kinetics of complex formation and dissociation, for example by SPR methods. The rate constants corresponding to the association and dissociation of the monovalent complex are the association rate constant k a (or k on ) and the dissociation rate constant k d (or k off ) is called. D is the equation K D =k d / ka Through, k a and k d According to the above definition, a comparison of the binding affinities associated with different molecular interactions, e.g., the binding affinities of different antibodies to a given antigen, is related to the K D The comparison may be made by comparing the values.
[0101] As used herein, the term "binding specificity" refers to the interaction of a molecule, such as an antibody or a fragment thereof, with a single exclusive antigen, or with a limited number of highly homologous antigens (or epitopes). In contrast, an antibody that can specifically bind to the spike (S) protein of SARS-CoV-2 cannot bind to dissimilar molecules.
[0102] The specificity of interaction and the value of equilibrium binding constant can be directly determined by well-known methods.Standard assays for evaluating the ability of ligands (such as antibodies) to bind to their targets are known in the art, and include, for example, ELISA, Western blot, RIA and flow cytometry analysis.The binding kinetics and binding affinity of antibody can also be evaluated by standard assays known in the art, such as SPR.
[0103] The term "naturally occurring" as used herein as applied to an object refers to the fact that the object can be found in nature. For example, a polypeptide or polynucleotide sequence present in an organism (including a virus) that can be isolated from a natural source and has not been deliberately modified by humans in a laboratory is naturally occurring.
[0104] A "polypeptide" refers to a chain that includes at least two consecutively linked amino acid residues, with no upper limit on the length of the chain. One or more amino acid residues in a protein may include modifications, such as, but not limited to, glycosylation, phosphorylation, or disulfide bond formation. A "protein" may include one or more polypeptides.
[0105] As used herein, the term "nucleic acid molecule" is intended to include DNA molecules and RNA molecules. A nucleic acid molecule may be single-stranded or double-stranded and may be cDNA.
[0106] The term "subject" includes humans and other mammalian subjects receiving either prophylactic or therapeutic treatment. As used herein, the term "subject" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, e.g., mammals and non-mammals, e.g., non-human primates, sheep, dogs, cows, chickens, amphibians, reptiles, etc.
[0107] As used herein, the terms "ug" and "uM" are used interchangeably with "μg" and "μM," respectively.
[0108] "Administering" as used herein refers to the physical introduction of a composition containing a therapeutic agent into a subject using any of a variety of methods and delivery systems known to those skilled in the art. Different routes of administration for the antibodies described herein include intravenous, intraperitoneal, intramuscular, subcutaneous, spinal or other parenteral routes of administration, for example, by injection or infusion.
[0109] The phrase "parenteral administration" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, but is not limited to, intravenous, intraperitoneal, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion, and in vivo electroporation.
[0110] Alternatively, the antibodies described herein can be administered via a non-parenteral route, such as a topical, epidermal or mucosal route of administration, e.g., intranasally, orally, vaginally, rectally, sublingually or topically. Administering can also be performed, e.g., once, multiple times, and / or over one or more extended periods of time.
[0111] As used herein, a "vaccine composition" refers to a pharmaceutical composition comprising at least one antibody or antigen-binding portion thereof of the present invention, capable of providing active and / or passive immunity. As used herein, "active immunity" refers to inducing or enhancing a subject's immune response to an antigen. As used herein, "passive immunity" refers to supplementing a subject's immune response to an antigen or pathogen by providing an antibody and / or antigen-binding portion thereof that neutralizes the antigen.
[0112] The inventors devoted themselves to solving the problems of the present invention and succeeded in finding novel and useful ultra-potent human monoclonal antibodies against SARS-associated coronaviruses, which have superior neutralizing potency against circulating SARS-CoV-2 variants of concern and emerging escape variants, compared to publicly available neutralizing antibodies.
[0113] We recently demonstrated that a small proportion of COVID-19 recovered individuals mount very strong antibody responses to SARS-CoV-2 with a high degree of cross-reactivity to SARS-CoV-1 (Vanshylla, K. et al., (2021). Cell Host Microbe 29, 917-929). In these elite neutralizers, we performed a detailed analysis of the antibody response at the single B cell level, including the isolation and characterization of 126 monoclonal antibodies from 10 individuals.
[0114] Sequence analysis of 1,361 SARS-CoV-2-reactive B cells revealed a mostly polyclonal, but convergent antibody response. Some antibodies were sarbecovirus cross-reactive, and some showed merbecovirus and envecovirus reactivity. Based on the comprehensive neutralization map, several broadly neutralizing antibodies (bNAbs) could be identified as part of the present invention as highly effective against circulating Wu-01, B.1, B.1.1.7, B1.351, B.1.429, B.1.617, and B.1.617.2 SARS-CoV-2 variants, as well as various prominent sites of antigenic escape.
[0115] Furthermore, we were able to identify new potential sites of antigenic escape based on a time-series phylogenetic tree of globally circulating SARS-CoV-2 variants using over 716,806 unique quality-controlled sequences (data not shown). Using this global data, we identified four RBD variants, R346S, Q414H, N440K, and T478K, as potential candidates for emergent spike escape sites.
[0116] Although these variants are not currently circulating at high frequency, they may play a role in the future and therefore have been included in the analysis of neutralizing potency of the antibodies of the invention. Surprisingly, the antibodies of the invention were also able to neutralize these RBD variants with high potency, in contrast to clinically tested antibodies such as DZIF-10c, S309, or REGN10987.
[0117] Thus, these bNAbs isolated from elite neutralizers will serve as a critical resource to combat current circulating and emerging SARS-CoV-2 variants, as well as future potential CoV pandemics caused by such viruses.
[0118] Thus, the present invention provides an antibody or antigen-binding fragment thereof against a SARS-associated coronavirus, the antibody or antigen-binding fragment thereof comprising: R200-1B9 (having a CDR-H1 amino acid sequence of SEQ ID NO: 27, a CDR-H2 amino acid sequence of SEQ ID NO: 28, a CDR-H3 amino acid sequence of SEQ ID NO: 29, a CDR-L1 amino acid sequence of SEQ ID NO: 30, a CDR-L2 amino acid sequence of SEQ ID NO: 31, and a CDR-L3 amino acid sequence of SEQ ID NO: 32), R207-2F11 (having a CDR-H1 amino acid sequence of SEQ ID NO: 33, a CDR-H2 amino acid sequence of SEQ ID NO: 34, a CDR-H3 amino acid sequence of SEQ ID NO: 35, a CDR-L1 amino acid sequence of SEQ ID NO: 36, a CDR-L2 amino acid sequence of SEQ ID NO: 37, and a CDR-L3 amino acid sequence of SEQ ID NO: 38), R40-1G8 (having a CDR-H1 amino acid sequence of SEQ ID NO: 39, a CDR-H2 amino acid sequence of SEQ ID NO: 40, a CDR-H3 amino acid sequence of SEQ ID NO: 41, a CDR-L1 amino acid sequence of SEQ ID NO: 42, a CDR-L2 amino acid sequence of SEQ ID NO: 43, and a CDR-L3 amino acid sequence of SEQ ID NO: 44), R568-2G5 (having a CDR-H1 amino acid sequence of SEQ ID NO: 45, a CDR-H2 amino acid sequence of SEQ ID NO: 46, a CDR-H3 amino acid sequence of SEQ ID NO: 47, a CDR-L1 amino acid sequence of SEQ ID NO: 48, a CDR-L2 amino acid sequence of SEQ ID NO: 49, and a CDR-L3 amino acid sequence of SEQ ID NO: 50), R568-2B11 (having a CDR-H1 amino acid sequence of SEQ ID NO: 51, a CDR-H2 amino acid sequence of SEQ ID NO: 52, a CDR-H3 amino acid sequence of SEQ ID NO: 53, a CDR-L1 amino acid sequence of SEQ ID NO: 54, a CDR-L2 amino acid sequence of SEQ ID NO: 55, and a CDR-L3 amino acid sequence of SEQ ID NO: 56), R207-2G4 (having a CDR-H1 amino acid sequence of SEQ ID NO: 57, a CDR-H2 amino acid sequence of SEQ ID NO: 58, a CDR-H3 amino acid sequence of SEQ ID NO: 59, a CDR-L1 amino acid sequence of SEQ ID NO: 60, a CDR-L2 amino acid sequence of SEQ ID NO: 61, and a CDR-L3 amino acid sequence of SEQ ID NO: 62), R40-1C8 (having a CDR-H1 amino acid sequence of SEQ ID NO: 63, a CDR-H2 amino acid sequence of SEQ ID NO: 64, a CDR-H3 amino acid sequence of SEQ ID NO: 65, a CDR-L1 amino acid sequence of SEQ ID NO: 66, a CDR-L2 amino acid sequence of SEQ ID NO: 67, and a CDR-L3 amino acid sequence of SEQ ID NO: 68), R568-2B9 (having a CDR-H1 amino acid sequence of SEQ ID NO: 69, a CDR-H2 amino acid sequence of SEQ ID NO: 70, a CDR-H3 amino acid sequence of SEQ ID NO: 71, a CDR-L1 amino acid sequence of SEQ ID NO: 72, a CDR-L2 amino acid sequence of SEQ ID NO: 73, and a CDR-L3 amino acid sequence of SEQ ID NO: 74), R568-1B3 (having a CDR-H1 amino acid sequence of SEQ ID NO: 75, a CDR-H2 amino acid sequence of SEQ ID NO: 76, a CDR-H3 amino acid sequence of SEQ ID NO: 77, a CDR-L1 amino acid sequence of SEQ ID NO: 78, a CDR-L2 amino acid sequence of SEQ ID NO: 79, and a CDR-L3 amino acid sequence of SEQ ID NO: 80), R568-2E1 (having a CDR-H1 amino acid sequence of SEQ ID NO: 81, a CDR-H2 amino acid sequence of SEQ ID NO: 82, a CDR-H3 amino acid sequence of SEQ ID NO: 83, a CDR-L1 amino acid sequence of SEQ ID NO: 84, a CDR-L2 amino acid sequence of SEQ ID NO: 85, and a CDR-L3 amino acid sequence of SEQ ID NO: 86), R568-1G9 (having a CDR-H1 amino acid sequence of SEQ ID NO: 87, a CDR-H2 amino acid sequence of SEQ ID NO: 88, a CDR-H3 amino acid sequence of SEQ ID NO: 89, a CDR-L1 amino acid sequence of SEQ ID NO: 90, a CDR-L2 amino acid sequence of SEQ ID NO: 91, and a CDR-L3 amino acid sequence of SEQ ID NO: 92), R121-1F1 (having a CDR-H1 amino acid sequence of SEQ ID NO: 93, a CDR-H2 amino acid sequence of SEQ ID NO: 94, a CDR-H3 amino acid sequence of SEQ ID NO: 95, a CDR-L1 amino acid sequence of SEQ ID NO: 96, a CDR-L2 amino acid sequence of SEQ ID NO: 97, and a CDR-L3 amino acid sequence of SEQ ID NO: 98), R259-1B9 (having a CDR-H1 amino acid sequence of SEQ ID NO: 99, a CDR-H2 amino acid sequence of SEQ ID NO: 100, a CDR-H3 amino acid sequence of SEQ ID NO: 101, a CDR-L1 amino acid sequence of SEQ ID NO: 102, a CDR-L2 amino acid sequence of SEQ ID NO: 103, and a CDR-L3 amino acid sequence of SEQ ID NO: 104) The present invention comprises a combination of heavy chain CDR1 to CDR3 and light chain CDR1 to CDR3 amino acid sequences of one antibody selected from the group consisting of:
[0119] In the context of the present invention, the antibodies produced and described herein may be used and claimed as fully monoclonal human antibodies or as any functional or antigen-binding fragment thereof. Preferably, any type of antibody or functional or antigen-binding fragment thereof should contain at least complementarity determining regions (CDRs) 1-3 of the heavy chain and CDRs 1-3 of the light chain of the antibody.
[0120] The CDR regions of the antibody sequences described herein are preferably defined according to the IMGT numbering scheme, which is an adaptation of the Chothia numbering scheme (ImMunoGeneTics information system™; Lefranc, M.-P. et al., IMGT, International ImMunoGeneTics Database, Nucleic Acids Res 27, 209-212 (1999); http: / / imgt.org).
[0121] CDRs can be easily and unambiguously determined by those skilled in the art based on general knowledge about the variable region heavy chain amino acid sequences and variable region light chain amino acid sequences of the antibody of the present invention and the information provided herein.
[0122] According to one preferred embodiment of the invention, the CDR sequences of the light and heavy chain sequences of the antibodies and antigen-binding fragments thereof described herein are as follows:
[0123] [Table 1] JPEG2024542793000002.jpg106168
[0124] According to one embodiment of the invention, the antibody or antigen-binding fragment thereof comprises the heavy chain amino acid sequence of the antibody R200-1B9 (SEQ ID NO: 121), or the heavy chain amino acid sequence of the antibody R207-2F11 (SEQ ID NO: 123), or the heavy chain amino acid sequence of the antibody R40-1G8 (SEQ ID NO: 125), or the heavy chain amino acid sequence of the antibody R568-2G5 (SEQ ID NO: 127), or the heavy chain amino acid sequence of the antibody R568-2B11 (SEQ ID NO: 129), or the heavy chain amino acid sequence of the antibody R207-2G4 (SEQ ID NO: 131), or The heavy chain amino acid sequence of the antibody R40-1C8 (SEQ ID NO: 133), or the heavy chain amino acid sequence of the antibody R568-2B9 (SEQ ID NO: 135), or the heavy chain amino acid sequence of the antibody R568-1B3 (SEQ ID NO: 137), or the heavy chain amino acid sequence of the antibody R568-2E1 (SEQ ID NO: 139), or the heavy chain amino acid sequence of the antibody R568-1G9 (SEQ ID NO: 141), or the heavy chain amino acid sequence of the antibody R121-1F1 (SEQ ID NO: 143), or the heavy chain amino acid sequence of the antibody R259-1B9 (SEQ ID NO: 145).
[0125] According to one embodiment of the invention, the antibody or antigen-binding fragment thereof comprises the light chain amino acid sequence of the antibody R200-1B9 (SEQ ID NO: 122), or the light chain amino acid sequence of the antibody R207-2F11 (SEQ ID NO: 124), or the light chain amino acid sequence of the antibody R40-1G8 (SEQ ID NO: 126), or the light chain amino acid sequence of the antibody R568-2G5 (SEQ ID NO: 128), or the light chain amino acid sequence of the antibody R568-2B11 (SEQ ID NO: 130), or the light chain amino acid sequence of the antibody R207-2G4 (SEQ ID NO: 132), or The light chain amino acid sequence of antibody R40-1C8 (SEQ ID NO: 134), or the light chain amino acid sequence of antibody R568-2B9 (SEQ ID NO: 136), or the light chain amino acid sequence of antibody R568-1B3 (SEQ ID NO: 138), or the light chain amino acid sequence of antibody R568-2E1 (SEQ ID NO: 140), or the light chain amino acid sequence of antibody R568-1G9 (SEQ ID NO: 142), or the light chain amino acid sequence of antibody R121-1F1 (SEQ ID NO: 144), or the light chain amino acid sequence of antibody R259-1B9 (SEQ ID NO: 146).
[0126] According to a preferred embodiment of the invention, the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 121 and a light chain amino acid sequence of SEQ ID NO: 122, or the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 123 and a light chain amino acid sequence of SEQ ID NO: 124, or the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 125 and a light chain amino acid sequence of SEQ ID NO: 126, or the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 127 and a light chain amino acid sequence of SEQ ID NO: 128, or the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 129 and a light chain amino acid sequence of SEQ ID NO: 130, or the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 131 and a light chain amino acid sequence of SEQ ID NO: 132, or the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 133. or the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 135 and a light chain amino acid sequence of SEQ ID NO: 136, or the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 137 and a light chain amino acid sequence of SEQ ID NO: 138, or the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 139 and a light chain amino acid sequence of SEQ ID NO: 140, or the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 141 and a light chain amino acid sequence of SEQ ID NO: 142, or the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 143 and a light chain amino acid sequence of SEQ ID NO: 144, or the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 145 and a light chain amino acid sequence of SEQ ID NO: 146.
[0127] According to a particular embodiment of the invention, the antibody consists of two heavy chains of sequence SEQ ID NO: 121 and two light chains of sequence SEQ ID NO: 122, or the antibody consists of two heavy chains of sequence SEQ ID NO: 123 and two light chains of sequence SEQ ID NO: 124, or the antibody consists of two heavy chains of sequence SEQ ID NO: 125 and two light chains of sequence SEQ ID NO: 126, or the antibody consists of two heavy chains of sequence SEQ ID NO: 127 and two light chains of sequence SEQ ID NO: 128, or the antibody consists of two heavy chains of sequence SEQ ID NO: 129 and two light chains of sequence SEQ ID NO: 130, or the antibody consists of two heavy chains of sequence SEQ ID NO: 131 and two light chains of sequence SEQ ID NO: 132, or the antibody consists of two heavy chains of sequence SEQ ID NO: 133. and two light chains of sequence SEQ ID NO: 134, or the antibody consists of two heavy chains of sequence SEQ ID NO: 135 and two light chains of sequence SEQ ID NO: 136, or the antibody consists of two heavy chains of sequence SEQ ID NO: 137 and two light chains of sequence SEQ ID NO: 138, or the antibody consists of two heavy chains of sequence SEQ ID NO: 139 and two light chains of sequence SEQ ID NO: 140, or the antibody consists of two heavy chains of sequence SEQ ID NO: 141 and two light chains of sequence SEQ ID NO: 142, or the antibody consists of two heavy chains of sequence SEQ ID NO: 143 and two light chains of sequence SEQ ID NO: 144, or the antibody consists of two heavy chains of sequence SEQ ID NO: 145 and two light chains of sequence SEQ ID NO: 146.
[0128] According to a preferred embodiment of the invention, the antibodies used as a source of sequences contained in the antibodies or antigen-binding fragments thereof according to the invention are R200-1B9, R207-2F11, R40-1G8, R568-2G5, R568-2B11, R207-2G4, R40-1C8, R568-2B9, R568-1B3, R568-2E1, R568-1G9, R121-1F1, and R259 -1B9, preferably selected from the group including R200-1B9, R207-2F11, R40-1G8, R568-2G5, R568-2B11, R207-2G4, R40-1C8, R568-2B9, and R568-1B3, more preferably selected from the group including R200-1B9, R207-2F11, R40-1G8, and R568-2G5.
[0129] According to another preferred embodiment of the invention, the antibody used as the source of the sequences contained in the antibody or antigen-binding fragment thereof according to the invention is selected from the group comprising R200-1B9, R207-2F11 and R568-1G9, preferably from R207-2F11 and R568-1G9. In addition to having a very high and broad neutralizing potency against all mutations and variants, these antibodies are characterized by a very good neutralizing potency against omicron variants.
[0130] In one embodiment of the invention, the antibody used as the source of the sequence contained in the antibody of the invention is R200-1B9. In another embodiment of the invention, the antibody used as the source of the sequence contained in the antibody of the invention is R207-2F11. In another embodiment of the invention, the antibody used as the source of the sequence contained in the antibody of the invention is R40-1G8. In another embodiment of the invention, the antibody used as the source of the sequence contained in the antibody of the invention is R568-2G5.
[0131] In another embodiment of the invention, the antibody used as the source of the sequences contained in the antibody of the invention is R121-3G2. This antibody can efficiently cross-neutralize the SARS-related coronavirus strain SARS-CoV-1 and the bat coronavirus WIV-1, in addition to different variants of SARS-CoV-2. In yet another embodiment of the invention, the antibody used as the source of the sequences contained in the antibody of the invention is R40-1E1. This antibody can also efficiently cross-neutralize the SARS-related coronavirus strain SARS-CoV-1 and the bat coronavirus WIV-1, in addition to different variants of SARS-CoV-2.
[0132] According to another preferred embodiment of the invention, the SARS-associated coronavirus strain is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
[0133] According to one embodiment of the invention, the amino acid sequence of the CDR or variable region contained in the antibody or antigen-binding fragment thereof according to the invention is derived from an antibody capable of neutralizing each of the SARS-CoV-2 strains B.1, B.1.1.7, B.1.351, B.1.429, B.1.617 and B.1.617.2 in a pseudovirus neutralization assay described in the description with an IC50 of at most 0.4 μg / ml, preferably at most 0.1 μg / ml, more preferably at most 0.05 μg / ml, even more preferably at most 0.025 μg / ml, even more preferably at most 0.01 μg / ml and particularly preferably at most 0.0025 μg / ml.
[0134] According to another embodiment of the invention, the amino acid sequences of the CDRs or variable regions contained in the antibody or antigen-binding fragment thereof according to the invention are derived from an antibody capable of neutralizing each of the SARS-CoV-2 spike escape mutants 69-70del, K417E, N439K, K444Q, V445A, G446V, L452R, Y453F, L455F, G476S, S477N, E484K, F486V, F490S, Q493R, Q493K, S494P, N501Y in a pseudovirus neutralization assay described in the description with an IC50 of at most 1.3 μg / ml, preferably at most 0.5 μg / ml, more preferably at most 0.05 μg / ml, even more preferably at most 0.02 μg / ml, particularly preferably at most 0.01 μg / ml.
[0135] According to another embodiment of the invention, the amino acid sequences of the CDRs or variable regions contained in the antibody or antigen-binding fragment thereof are obtained from an antibody capable of neutralizing each of the emerging SARS-CoV-2 escape variants R346S, Q414H, N440K, and T478K in a pseudovirus neutralization assay described in the description with an IC50 of at most 0.0015 μg / ml.
[0136] According to an embodiment of the invention, the amino acid sequence of the CDR or variable region contained in the antibody or antigen-binding fragment thereof according to the invention neutralizes the SARS-CoV-2 variant Wu in the pseudovirus neutralization assay described in the description across all variants and mutants with an average IC50 of at most 0.08 μg / ml, preferably at most 0.025 μg / ml, more preferably at most 0.01 μg / ml, even more preferably at most 0.006 μg / ml, particularly preferably at most 0.002 μg / ml. -01, B.1, B.1.1.7, B.1.351, B.1.429, B.1.617 and B.1.617.2, as well as antibodies capable of neutralizing SARS-CoV-2 escape mutants 69-70del, K417E, N439K, K444Q, V445A, G446V, L452R, Y453F, L455F, G476S, S477N, E484K, F486V, F490S, Q493R, Q493K, S494P, N501Y, R346S, Q414H, N440K, and T478K.
[0137] According to the present invention, an IC 50 Pseudovirus neutralization assays to determine IgG neutralizing activity are performed as described in the section below, "Pseudovirus neutralization assays to determine IgG neutralizing activity."
[0138] According to one embodiment of the invention, the antibody or antigen-binding fragment thereof according to the invention does not exhibit autoreactivity, defined as detectable binding, when tested against permeabilized HEp-2 cells using an antinuclear antibody (ANA) test kit (NOVA-Lite HEp-2 ANA kit; Inova Diagnostics) at a concentration of 100 μg / ml of the antibody or antigen-binding fragment thereof.
[0139] According to a preferred embodiment of the present invention, the assay for measuring autoreactivity is performed as described in the section "Hep-2 Autoreactivity Assay" below.
[0140] According to an embodiment of the invention, the CDR sequences of the light and heavy chain sequences of the antibodies described herein are as follows:
[0141] [Table 2]
[0142] According to one embodiment of the invention, the antibody has the heavy chain amino acid sequence of antibody R121-3G2 (SEQ ID NO: 147) or the heavy chain amino acid sequence of antibody R40-1E1 (SEQ ID NO: 149). According to an embodiment of the invention, the antibody has the light chain amino acid sequence of antibody R121-3G2 (SEQ ID NO: 148) or the light chain amino acid sequence of antibody R40-1E1 (SEQ ID NO: 150).
[0143] According to a preferred embodiment of the invention, the antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 147 and the light chain amino acid sequence of SEQ ID NO: 148, or the antibody comprises the heavy chain amino acid sequence of SEQ ID NO: 149 and the light chain amino acid sequence of SEQ ID NO: 150.
[0144] According to a particular embodiment of the invention, the antibody consists of two heavy chains of sequence SEQ ID NO: 147 and two light chains of sequence SEQ ID NO: 148, or the antibody consists of two heavy chains of sequence SEQ ID NO: 149 and two light chains of sequence SEQ ID NO: 150.
[0145] Generally, the antibodies or antigen-binding fragments thereof described herein further encompass antibody amino acid sequences that are at least 80% identical to the sequences defined above, so long as they are still directed against the spike (S) protein of SARS-CoV-2, such as SEQ ID NO: 151, and preferably still directed against the receptor binding domain (RBD) of the spike (S) protein of SARS-CoV-2, such as SEQ ID NO: 152.
[0146] According to one embodiment, the specific sequence of the spike (S) protein of SARS-CoV-2 of SEQ ID NO: 151 or its receptor binding domain of SEQ ID NO: 152, against which the antibody or antigen-binding fragment thereof is directed, may further comprise one or more of the sequence mutations 69-70del, R346S, Q414H, K417E, N439K, N440K, K444Q, V445A, G446V, L452R, Y453F, L455F, G476S, S477N, T478K, E484K, F486V, F490S, Q493R, Q493K, S494P and N501Y.
[0147] According to another embodiment, the specific sequence of the SARS-CoV-2 spike (S) protein of SEQ ID NO: 151 or its receptor binding domain of SEQ ID NO: 152 to which the antibody or antigen-binding fragment thereof is directed may be obtained from one of the commonly known SARS-CoV-2 variants Wu01, B.1, B.1.1.7, B1.351, B.1.429, B.1.617, or B.1.617.2.
[0148] Sequence variations encompassed herein are meant to include sequences with minor variations in the antibody amino acid sequence, i.e., conservative variations, that do not interfere with the structural folding and affinity of the antibody to the spike (S) protein. Preferably, deviations in the amino acid sequence that result in at least 80%, 85%, 90% or 95% overall identity with the individual sequences explicitly disclosed herein are present only outside the CDR regions of the antibodies according to the invention. In particular, the invention encompasses antibody amino acid sequences with 1, 2, 3, 4, 5 or 6 variations within the constant regions of the antibody.
[0149] The antibody according to the present invention is preferably of human origin.Therefore, at least the sequences other than CDRs, such as the framework and constant regions of the antibody, are preferably of human origin or can be of human origin.Furthermore, the antibody according to the present invention is preferably monoclonal.
[0150] In a preferred embodiment, the antibody is a monoclonal antibody or a fragment thereof that retains binding specificity and the ability to neutralize infectious pathogens.In a preferred embodiment, the antibody is an IgG1, IgG2, IgG3, or IgG4 antibody.For example, the antibody can be an antibody that comprises the Fc domain of any human IgG isotype (e.g., IgG1, IgG2, IgG3, or IgG4).
[0151] Optionally, the antigen-binding compound consists of or comprises a Fab, Fab', Fab'-SH, F(ab)2, Fv, a diabody, a single-chain antibody fragment, or a multispecific antibody comprising multiple different antibody fragments.
[0152] In the present invention, an antibody or antigen-binding fragment against the spike (S) protein of SARS-CoV-2 means an antibody that binds to the spike (S) protein of SARS-CoV-2 with at least 10-fold, more preferably at least 50-fold, and particularly preferably at least 100-fold, higher affinity compared to an unrelated epitope, protein or protein region.
[0153] It is a trivial task for a person skilled in the art to determine whether an antibody showing a certain degree of identity is directed against the spike (S) protein of SARS-CoV-2 based on the above or general knowledge.
[0154] The determination of percent identity between two sequences is accomplished according to the present invention by using the mathematical algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. USA (1993) 90:5873-5877). Such an algorithm is the basis of the BLASTN and BLASTP programs of Altschul et al. (J. Mol. Biol. (1990) 215:403-410). BLAST nucleotide searches are performed with the BLASTN program. To obtain gapped alignments for comparison purposes, Gapped BLAST is utilized as described by Altschul et al. (Nucleic Acids Res. (1997) 25:3389-3402). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs are used.
[0155] According to a preferred embodiment of the present invention, the antibody amino acid sequences form part of the present invention consisting of or comprising a nucleic acid sequence which is at least 85% identical, more preferably at least 90% identical, even more preferably at least 95% identical to the sequences defined above and disclosed herein.
[0156] According to a preferred embodiment of the present invention, the SARS-associated coronavirus strain is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which may alternatively be referred to in the art as SARS-associated coronavirus 2. According to another preferred embodiment of the present invention, the SARS-associated coronavirus strain is Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV or SARS-CoV-1) or the bat SARS-like coronavirus WIV-1, preferably Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV or SARS-CoV-1).
[0157] According to another preferred embodiment of the invention, the antibody or antigen-binding fragment thereof is directed against the ectodomain of the spike (S) protein of SARS-CoV-2.
[0158] According to a more preferred embodiment of the invention, the antibody or antigen-binding fragment thereof is directed against the Wu01 spike (S) homotrimer of SARS-CoV-2 as described in Hoffmann M. et al. (2020). Cell 181, 271-280 (EPI_ISL_406716). This viral isolate has been intensively studied and is the best understood at the time of filing.
[0159] However, preferably, the antibody or antigen-binding fragment thereof should also be directed against the equivalent sequences of other viral variants. According to a particular embodiment, the antibody or antigen-binding fragment thereof is directed against the receptor binding domain (RBD) of the spike (S) protein of SARS-CoV-2 (SEQ ID NO: 152).
[0160] According to a preferred embodiment of the invention, the antibody or antigen-binding fragment thereof does not exhibit autoreactivity to human cells defined as a detectable binding pattern when tested against permeabilized HEp-2 cells using an antinuclear antibody (ANA) test kit (NOVA-Lite HEp-2 ANA kit; Inova Diagnostics) at a concentration of 100 μg / ml of the antibody or antigen-binding fragment thereof. Alternatively, and preferably, other assays known in the art may be used to determine or exclude autoreactivity of the antibody or antigen-binding fragment thereof.
[0161] In the description of this application, the name of the antibody may be used. It is pointed out that the antibody consists of a heavy chain and a light chain, which also form part of this description. When referring to an antibody by name or sequence number, it is understood that these methods of reference are interchangeable.
[0162] The present invention further relates to a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof according to the invention as defined and further described herein, and at least one pharma- ceutically acceptable excipient. In one embodiment, the pharmaceutical composition is a vaccine composition for a human and / or animal subject.
[0163] The present invention also encompasses a kit comprising an antibody or antigen-binding fragment thereof according to the invention as defined and further described herein, and a container.
[0164] In one aspect, the present invention is also directed to an antibody or antigen-binding fragment thereof according to the invention as defined and further described herein for use as a medicament, preferably for use as a vaccine, the pharmaceutical composition as described herein, and kits.
[0165] In another aspect, the present invention is also directed to an antibody or antigen-binding fragment thereof according to the invention as defined and further described herein, a pharmaceutical composition as described herein, and a kit for use in the treatment or prevention of a disease caused by a SARS-associated coronavirus in a human or animal subject, preferably for use in the treatment or prevention of a disease caused by SARS-associated coronavirus 2 (SARS-CoV-2) in a human or animal subject.
[0166] In one aspect, the present invention is directed to an antibody or antigen-binding fragment thereof according to the invention as defined and further described herein, a pharmaceutical composition as described herein, and a kit for use in the prevention of infection of a human and / or animal subject with a SARS-associated coronavirus, preferably infection of a human and / or animal subject with SARS-associated coronavirus 2 (SARS-CoV-2).
[0167] In another aspect, the present invention is directed to a method of treating or preventing a SARS-associated coronavirus infection or reducing the severity of disease in a human and / or animal subject, comprising administering to said subject a therapeutically effective amount of at least one antibody and / or antigen-binding fragment thereof described herein, preferably wherein the SARS-associated coronavirus is SARS-CoV-2.
[0168] In one embodiment of the invention, the antibodies and / or antigen-binding fragments thereof according to the invention are administered to a patient in need thereof by intravenous injection or infusion, subcutaneous injection, intramuscular injection, or inhalation application, preferably by intravenous injection.
[0169] In a preferred embodiment, the antibody or antigen-binding fragment thereof is administered by intravenous infusion at an absolute dose of up to 4000 mg, preferably up to 2000 mg, more preferably up to 1200 mg, even more preferably up to 600 mg, even more preferably up to 300 mg, and particularly preferably up to 150 mg.
[0170] The dose of the antibody or antigen-binding fragment thereof of the present invention administered to a subject can further vary depending on such things as the severity of the symptoms presented, as well as the age, sex, and health of the subject.
[0171] In another aspect of the invention, the antibody according to the invention is administered to a patient in need thereof by inhalation application, hi a preferred embodiment, the antibody is administered by inhalation application and is provided in a liquid pharmaceutical composition that is nebulized by a mesh or jet nebulizer prior to administration.
[0172] A pharmaceutical composition of the present invention is formulated to be compatible with its intended route of administration, including, but not limited to, parenteral, e.g., intravenous, intradermal, subcutaneous, oral, nasal (e.g., inhalation and inhalation through the mouth), transdermal (e.g., topical), transmucosal, and rectal administration.
[0173] In certain embodiments, the composition is formulated according to routine procedures as a pharmaceutical composition suitable for intravenous, subcutaneous, intramuscular, oral, nasal or local administration to humans.Typically, the composition for intravenous administration is a solution in sterile isotonic aqueous buffer.If necessary, the composition can also contain a solubilizing agent and a local anesthetic such as lignocaine to ease the pain at the injection site.
[0174] The method of the present invention can include the intrapulmonary administration of the composition that is formulated with aerosolizing agent, for example, by using an inhaler or nebulizer.See, for example, U.S. Patent No. 6,019,968, U.S. Patent No. 5,985,320, U.S. Patent No. 5,985,309, U.S. Patent No. 5,934,272, U.S. Patent No. 5,874,064, U.S. Patent No. 5,855,913, U.S. Patent No. 5,290,540 and U.S. Patent No. 4,880,078; and PCT Publication No. WO92 / 19244, WO97 / 32572, WO97 / 44013, WO98 / 31346 and WO99 / 66903, each of which is incorporated herein by reference in its entirety.
[0175] The methods of the invention may also include administration of compositions formulated for parenteral administration by injection (e.g., by bolus injection or continuous infusion).The pharmaceutical formulations of the invention may be provided in liquid or lyophilized form.
[0176] In one aspect, the invention relates to a nucleic acid encoding an antibody or antigen-binding fragment thereof described herein. In another aspect, the invention relates to an expression vector comprising a nucleic acid described herein in operative association with an expression control sequence.
[0177] In another aspect, the invention relates to a host cell comprising a nucleic acid described herein.In one aspect, the invention relates to a host cell comprising an expression vector described herein.
[0178] In another aspect, the present invention provides a method for producing a composition comprising: (a) culturing a host cell described herein under conditions that allow for expression of the antibody or antigen-binding fragment thereof; (b) recovering the antibody or antigen-binding fragment thereof; The present invention relates to a method for producing the antibodies or antigen-binding fragments described herein, comprising:
[0179] In another embodiment, the present invention relates to an antibody or antigen-binding fragment thereof against SARS-associated coronavirus 2 (SARS-CoV-2) as described herein for use in a medicament in combination with at least one further antibody against SARS-associated coronavirus 2 (SARS-CoV-2), wherein said further antibody has a different binding specificity.
[0180] In another aspect, the present invention is also directed to the use of an antibody or an antigen-binding fragment thereof according to the invention or a pharmaceutical composition of the invention in the manufacture of a medicament for the treatment of a disease caused by a SARS-associated coronavirus in a human or animal subject, preferably for the treatment or prevention of COVID-19 in a human or animal subject.
[0181] All embodiments of the invention described herein are deemed combinable in any combination, unless one skilled in the art would deem such combinations technically meaningless. EXAMPLES
[0182] SARS-CoV-2-infected individuals and specimen collection Blood samples were collected from donors who provided written consent under protocols 20-1187 and 16-054 approved by the Institutional Review Board (IRB) of the University of Cologne.
[0183] Serum, plasma and whole blood sample processing Blood samples were collected into heparin syringes or EDTA monovette tubes (Sarstedt) and fractionated into plasma and peripheral blood mononuclear cells (PBMCs) by density gradient centrifugation using Histopaque-1077 (Sigma). Plasma aliquots were stored at -80°C until use. Serum was collected from serum gel tubes (Sarstedt) by centrifugation and stored at -80°C until use. PBMCs were stored at -150°C until use.
[0184] Isolation of IgG from serum and plasma samples To isolate total IgG, 0.5–1 mL of plasma was heat inactivated at 56 °C for 45 min and incubated with Protein G Sepharose 4 Fast Flow beads (GE Healthcare) in PBS (Gibco) overnight at 4 °C. The next day, the beads were washed with PBS (Gibco) on a chromatography column (BioRad) and Protein G-bound IgG was eluted using 0.1 M glycine pH = 3 and immediately buffered with 1 M Tris pH = 8. Buffer exchange into PBS (Gibco) was performed using a 30 kDa cut-off Amicon Ultra-15 column (Millipore) and the purified IgG was stored at 4 °C.
[0185] cell line VeroE6, HEK-293T and 293T-ACE2 cells were maintained in DMEM (Gibco) containing 10% FBS, 1% PS, 1 mM L-glutamine and 1 mM sodium pyruvate. Cells were grown on tissue culture treated dishes in T75 flasks (Sarstedt) at 37°C and 5% CO2. 293-6E cells were maintained in FreeStyle Expression Medium (Thermo Fisher) at 37°C and 6% CO2 and kept under constant shaking at 110-120 rpm.
[0186] Single B cell sorting A prefusion spike-confirmed SARS-CoV-2 variant called HexaPro (Hsieh, CL et al., (2020). Science 369, 1501-1505) was used as a bait protein to sort spike-specific B cells from elite neutralizers using a two-color sorting strategy. HexaPro protein was labeled using DyLight 488 or Dylight 650 antibody labeling kits (Thermo Fisher) according to the manufacturer's protocol. B cells were enriched from the peripheral blood mononuclear cell (PBMC) fraction using a CD19 Microbeads kit (Miltenyi Biotec) according to the manufacturer's protocol.
[0187] Enriched B cells were stained with antibodies against human CD20 (AF700-labeled; clone 2H7; BD Biosciences catalog #560631) and human IgG (PE-labeled; clone G18-145; BD Biosciences catalog #555787), DAPI (Thermo Fisher catalog #D1306), HexaPro-Dylight-488, and HexaPro-Dylight-650. B cells that were DAPI negative, CD20 positive, IgG positive, HexaPro-Dylight-488 positive, and HexaPro-Dylight-650 positive were sorted into 96-well plates containing sorting buffer consisting of 0.2 μl RNAsin (40 U / μl Promega), 0.1 μl RNAseOut (40 U / μl Thermo Fisher), 0.2 μl 10X PBS, 0.4 μl DTT (100 mM Promega), and 3.1 μl nuclease-free H2O (Thermo Fisher). Sorting was performed on a BD FACSAria™ Fusion cell sorter (Becton Dickinson) and sorted cells were frozen at -80°C until further processing.
[0188] Single-cell cDNA production and PCR Sorted single B cells were lysed with 0.75 μl Random Hexamer Primer (200 ng / μl Thermo Fisher), 0.5 μl NP-40 (10% Thermo Fisher), 0.15 μl RNAseOUT (100 mM Thermo Fisher), and 5.6 μl nuclease-free H2O (Thermo Fisher) at 65°C for 1 min. Then, 2 μl of nuclease-free HO (Thermo Fisher), 3 μl of 5× RT buffer (Invitrogen), 0.5 μl of dNTPs (25 mM Thermo Fisher), 1 μl of DTT (100 mM Invitrogen), 0.1 μl of RNAsin (40 U / μl Promega), 0.1 μl of RNaseOUT (40 U / μl Thermo Fisher), and 0.25 μl of Superscript IV (200 U / μl Invitrogen) were added and reverse transcription was performed by incubating at RT for 10 min, 42° C. for 10 min, 25° C. for 10 min, 50° C. for 10 min, and 94° C. for 5 min.
[0189] Individual antibody sequences were amplified using semi-nested PCR. Heavy, kappa and lambda chains were simultaneously amplified in a first round of PCR using Platinum Taq™ DNA polymerase (Thermo Fisher) with 5'oPR-IGHV, oPR-IGKV and oPR-IGLV primer mix (Kreer, C. et al. (2020). J Immunol Methods 480, 112752) along with 3'Cg-RT (Ozawa, T. et al. (2006). Biotechniques 40, 469-470, 472, 474), 3'Cκ543 (Tiller, T. et al. (2008). J Immunol Methods 329, 112-124), and 3'Cκ494 (Tiller et al., 2008).
[0190] The first PCR was carried out at 94°C for 1 min, followed by 50 cycles of 94°C for 30 s, 57°C for 30 s, and 72°C for 55 s, with a final extension at 72°C for 5 min.
[0191] In the second PCR, the antibody chains were amplified in separate reactions using the following primer pairs: 5'oPR-IGHV+3'IgG internal (Tiller et al., 2008) (heavy chain), 5'oPR-IGKV+3'Cκ494 (kappa chain), and 5'oPR-IGLV+3'XhoI Cλ (Tiller et al., 2008) (lambda chain). The second PCR was performed at 94°C for 1 min, followed by 50 cycles of 94°C for 30 s, 57°C for 30 s, and 72°C for 45 s, with a final extension at 72°C for 5 min. The second PCR products were sequenced by Sanger sequencing for subsequent sequence analysis.
[0192] Antibody sequence analysis B cell sequences with a minimum length of 240 nucleotides and an average Phred score of 28 amino acids or more were annotated with IgBLAST (Ye, J. et al. (2013). Nucleic Acids Res 41, W34-40) and trimmed from framework region (FWR) 1 to the end of the J gene of the variable region. Basal cells with a Phred score less than 16 were masked and sequences with more than 15 masked nucleotides, frameshifts or stop codons were excluded from further analysis.
[0193] From these produced sequences, clonality was analyzed by grouping identical V genes and determining their pairwise Levenshtein distances in CDRH3. Individual sequences were grouped into clones if they shared the same V gene and had a minimum CDRH3 identity of 75%. Sequences remaining after 10 rounds of randomized input were designated as non-clonal. CDRH3 length was calculated based on IMGT numbering, and the % of sequences represents sequences with a particular V gene out of all sequences in an individual.
[0194] Antibody cloning for protein synthesis Cloning of single B cell-derived antibodies was performed according to a previously published protocol (Gieselmann, L. et al., (2021). Nat Protoc 16, 3639-3671). The first round PCR products were used to amplify the variable regions of each antibody chain in separate reactions using the 5' primers SLIC-oPR-IGHV, SLIC-oPR-IGKV and SLIC-oPR-IGLV (Kreer et al., 2020) and the 3' primers SLIC_IgG_HC_rev, SLIC_KC_rev and SLIC_LC_rev for the heavy, kappa and lambda chains, respectively (Tiller et al., 2008).
[0195] PCR was performed using Q5 Hot Start High Fidelity DNA Polymerase (NEB) at 98°C for 30 seconds, followed by 35 cycles of 98°C for 10 seconds and 72°C for 45 seconds, with a final extension at 72°C for 2 minutes. PCR products were purified using the NucleoSpin™ 96 PCR Clean-up Kit (Macherey-Nagel) according to the manufacturer's protocol and cloned into the respective pIg expression vector (pIgG1, pIgK, or pIgL) by restriction digestion and SLIC assembly (von Boehmer, L. et al. (2016). Nat Protoc 11, 1908-1923).
[0196] antibody synthesis Antibodies were produced by transfection of 293-6E cells (National Research Council Canada) with 0.5 μg of heavy chain plasmid and 0.5 μg of light chain plasmid per ml of 293-6E culture using branched polyethyleneimine (PEI) 25 kDa (Sigma-Aldrich). Cells were maintained at 37°C and 6% CO2 in FreeStyle 293 Expression Medium (Thermo Fisher) and 0.2% penicillin / streptomycin at 110–120 rpm. Seven days after transfection, cells were centrifuged and cell culture supernatants were harvested, filtered through 0.45 μm Nalgene Rapid Flow filters (Thermo Fisher), and incubated overnight at 4°C with Protein G Sepharose 4 Fast Flow (GE Healthcare).
[0197] The antibody-bound Sepharose beads were washed with PBS (Gibco) on a chromatography column (BioRad) and the antibody was eluted using 0.1 M glycine pH = 3 and immediately buffered with 1 M Tris pH = 8. Afterwards, a buffer exchange into PBS (Gibco) was performed using a 50 kDa Amicon Ultra-15 spin column (Millipore) and the antibody was stored at 4°C.
[0198] Cloning of SARS-CoV-2 spike variants The codon-optimized SARS-CoV-2 Wu01 spike (Hoffmann, M. et al., (2020). Cell 181, 271-280.e8) (isolate EPI_ISL_406716) was cloned into the pCDNA™3.1 / V5-HisTOPO vector (Invitrogen). The D614G (B.1), 69-70 deletion and RBD mutants were generated by introducing the corresponding amino acid mutations using the Q5® Site-Directed Mutagenesis Kit (NEB) according to the manufacturer's protocol.
[0199] SARS-2-S RBD variants were generated in the B.1 background and included R346S; Q414H; K417E; N439K; N440K; K444Q; V445A; G446V; Y453F; G476S; S477N; T478K; E484K; F486V; F490S; Q493R; Q493K; S494P and N501Y. SARS-CoV-2 spike variants B1.1.7, B1.351, B.1.429, B.1.617 and B.1.617.2 were generated by introducing the corresponding amino acid mutations (see FIG. 5) using PCR and HiFi assembly of overlapping segments (NEBuilder® HiFi DNA Assembly Kit, New England Biolabs) according to the manufacturer's protocol. The omicron variants of SARS-CoV-2 tested in this study are defined as BA.1 lineage according to Pango v.3.1.17 2021-11-25.
[0200] Compared to the spike glycoprotein amino acid sequence of the Wu01 reference strain (GISAID accession ID EPI_ISL_406716; virus name: hCoV-19 / Wuhan / WHU01 / 2020), the Omicron variant (BA.1 lineage) used herein has the following changes in the spike glycoprotein amino acid sequence: A67V, del69-70, T95I, G142D, del143-145, N211I, del2 12, ins215EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, and L981F. The results obtained with the omicron variants are shown in FIG.
[0201] Production and titration of pseudoviral particles Pseudovirus particles were generated by co-transfection of individual plasmids encoding HIV-1 Tat, HIV-1 Gag / Pol, HIV-1 Rev, luciferase followed by IRES and ZsGreen (reagents described in Crawford, KHD et al. (2020). Viruses 12, 513), as well as spike proteins of SARS-CoV-2, SARS-CoV-1 or WIV-1. For pseudovirus production, pseudovirus-encoding plasmids were transfected into HEK 293T cells using FuGENE™ 6 Transfection Reagent (Promega) according to the manufacturer's protocol. At 48 and 72 hours after transfection, cell debris was centrifuged and viral culture supernatants were harvested and stored at -80 °C until use.
[0202] Each virus batch was titrated by infecting 293T-ACE2 cells (293T cells expressing the human ACE2 receptor) and after a 48 h incubation period at 37 °C and 5% CO2, luciferase activity was measured using a microplate reader (Berthold) after adding luciferin / lysis buffer (10 mM MgCl2, 0.3 mM ATP, 0.5 mM coenzyme A, 17 mM IGEPAL (all Sigma-Aldrich), and 1 mM D-luciferin (GoldBio) in Tris-HCL). There was a 1000-fold relative increase between infected and non-infected cells. Illumination Pseudovirus dilutions resulting in differential units (RLU) were used for pseudovirus neutralization assays.
[0203] Pseudovirus neutralization assay to determine IgG neutralizing activity To test the neutralization activity of IgG (including monoclonal antibodies), a 3-fold dilution series of IgG was prepared in neutralization assay medium (DMEM supplemented with 10% FBS, 100 U / ml penicillin, 100 U / ml streptomycin, 1 mM L-glutamine, and 1 mM sodium pyruvate). The diluted IgG was co-incubated with pseudovirus supernatants produced and titrated as described above (section "Production and titration of pseudovirus particles") for 1 h at 37°C and 5% CO2 in a total volume of 100 μL in a 96-well plate. The dilution series had a starting concentration (referring to the concentration during co-incubation of IgG and pseudovirus) of 10 μg / ml for monoclonal antibodies and 750 μg / ml for purified serum or plasma IgG. The IgG was then diluted with 1.25 × 10 IgG supplemented with polybrene at a final concentration of 5 μg / ml. 4 293T-ACE2 cells (cells described in Crawford et al., 2020) were added to each well.
[0204] After 48 hours of incubation at 37°C and 5% CO2, luciferase activity was measured using the luciferin / lysis buffer reagent described above (section "Generation and titration of pseudovirus particles"). 50 μl of cell culture supernatant was removed before adding 100 μl of luciferin / lysis buffer. After 2 minutes of lysis and mixing by pipetting, 150 μl of supernatant was transferred to another 96-well plate and RLU was measured in a microplate reader (measured at 1 second per well).
[0205] After subtracting the average background RLU of uninfected cells (wells containing cells not incubated with pseudovirus), the 50% inhibitory concentration (IC 50 ) was determined as the IgG concentration that resulted in a 50% reduction in RLU compared to the average of untreated virus control wells (wells containing cells and pseudovirus without IgG).
[0206] Plot agonist versus normalized dose-response curves with variable slopes using least-squares fitting method to measure IgG IC in GraphPad Prism 7.0 by using a nonlinear fit model 50 Based on this dose-response curve, the 50% Y value was used to calculate the corresponding X value or IC 50 Each IgG sample was measured in two independent experiments on different days and the average IC 50 Values reported.
[0207] SARS-CoV-2 True Virus Neutralization Assay Authentic SARS-CoV-2 (COV2-P3) was pre-grown from SARS-CoV-2 positive swab samples using VeroE6 cells as previously described (Vanshylla et al., 2021, Cell host & Microbe, 29(6):917-929.e4). For neutralization assays, five-fold serial dilutions of monoclonal IgG in DMEM containing 2% FBS, 1% PS, 1 mM L-glutamine and 1 mM sodium pyruvate were prepared and incubated at 37 °C for 1 h to incubate with 1000–2000 TCID 50 ), followed by addition of VeroE6 cells in DMEM (Gibco) containing 2% FBS, 1% PS, 1 mM L-glutamine and 1 mM sodium pyruvate. The dilution series had a starting concentration of 10 μg / ml for the monoclonal antibodies (referring to the concentration during the IgG and virus co-incubation).
[0208] After 4 days of incubation at 37°C and 5% CO2, neutralization was analyzed by observing cytopathic effect (CPE) using a bright field microscope, and the antibody concentration at the highest dilution well that did not show CPE was determined as the IC of that antibody. 100 All samples were measured in two independent experiments on separate days, and the average IC from all measurements was calculated. 100 reported.
[0209] Hep-2 autoreactivity assay Hep-2 cell autoreactivity assays were performed using the NOVA Lite Hep-2 ANA kit (Inova Diagnostics) with monoclonal antibodies at 100 μg / ml in DPBS according to the manufacturer's protocol. As a positive control, the Hep-2 cell-reactive HIV-1 neutralizing antibody 4E10 was included. Images were acquired using a Leica DMI3000 B microscope with an exposure time of 15 ms and a gain of 10. Images were processed in Adobe Photoshop and assembled in Adobe Illustrator CC2018®. None of the antibodies of the invention tested in this assay (R200-1B9, R207-2F11, R40-1G8, R568-2G5, R568-2B11, R207-2G4, R40-1C8, R568-2B9, R568-1B3, R568-2E1, R568-1G9 and R121-1F1) demonstrated autoreactivity in this assay (data not shown).
[0210] A summary of the results obtained with the antibodies of the invention is shown in Figures 2, 3, 4, 6 and 7.
Claims
1. An antibody or antigen-binding fragment thereof against SARS-associated coronavirus, R200-1B9 (having a CDR-H1 amino acid sequence of SEQ ID NO:27, a CDR-H2 amino acid sequence of SEQ ID NO:28, a CDR-H3 amino acid sequence of SEQ ID NO:29, a CDR-L1 amino acid sequence of SEQ ID NO:30, a CDR-L2 amino acid sequence of SEQ ID NO:31, and a CDR-L3 amino acid sequence of SEQ ID NO:32); R207-2F11 (having a CDR-H1 amino acid sequence of SEQ ID NO: 33, a CDR-H2 amino acid sequence of SEQ ID NO: 34, a CDR-H3 amino acid sequence of SEQ ID NO: 35, a CDR-L1 amino acid sequence of SEQ ID NO: 36, a CDR-L2 amino acid sequence of SEQ ID NO: 37, and a CDR-L3 amino acid sequence of SEQ ID NO: 38); R40-1G8 (having a CDR-H1 amino acid sequence of SEQ ID NO:39, a CDR-H2 amino acid sequence of SEQ ID NO:40, a CDR-H3 amino acid sequence of SEQ ID NO:41, a CDR-L1 amino acid sequence of SEQ ID NO:42, a CDR-L2 amino acid sequence of SEQ ID NO:43, and a CDR-L3 amino acid sequence of SEQ ID NO:44), R568-2G5 (having a CDR-H1 amino acid sequence of SEQ ID NO: 45, a CDR-H2 amino acid sequence of SEQ ID NO: 46, a CDR-H3 amino acid sequence of SEQ ID NO: 47, a CDR-L1 amino acid sequence of SEQ ID NO: 48, a CDR-L2 amino acid sequence of SEQ ID NO: 49, and a CDR-L3 amino acid sequence of SEQ ID NO: 50); R568-2B11 (having a CDR-H1 amino acid sequence of SEQ ID NO:51, a CDR-H2 amino acid sequence of SEQ ID NO:52, a CDR-H3 amino acid sequence of SEQ ID NO:53, a CDR-L1 amino acid sequence of SEQ ID NO:54, a CDR-L2 amino acid sequence of SEQ ID NO:55, and a CDR-L3 amino acid sequence of SEQ ID NO:56); R207-2G4 (having a CDR-H1 amino acid sequence of SEQ ID NO:57, a CDR-H2 amino acid sequence of SEQ ID NO:58, a CDR-H3 amino acid sequence of SEQ ID NO:59, a CDR-L1 amino acid sequence of SEQ ID NO:60, a CDR-L2 amino acid sequence of SEQ ID NO:61, and a CDR-L3 amino acid sequence of SEQ ID NO:62); R40-1C8 (having a CDR-H1 amino acid sequence of SEQ ID NO:63, a CDR-H2 amino acid sequence of SEQ ID NO:64, a CDR-H3 amino acid sequence of SEQ ID NO:65, a CDR-L1 amino acid sequence of SEQ ID NO:66, a CDR-L2 amino acid sequence of SEQ ID NO:67, and a CDR-L3 amino acid sequence of SEQ ID NO:68); R568-2B9 (having a CDR-H1 amino acid sequence of SEQ ID NO:69, a CDR-H2 amino acid sequence of SEQ ID NO:70, a CDR-H3 amino acid sequence of SEQ ID NO:71, a CDR-L1 amino acid sequence of SEQ ID NO:72, a CDR-L2 amino acid sequence of SEQ ID NO:73, and a CDR-L3 amino acid sequence of SEQ ID NO:74); R568-1B3 (having a CDR-H1 amino acid sequence of SEQ ID NO:75, a CDR-H2 amino acid sequence of SEQ ID NO:76, a CDR-H3 amino acid sequence of SEQ ID NO:77, a CDR-L1 amino acid sequence of SEQ ID NO:78, a CDR-L2 amino acid sequence of SEQ ID NO:79, and a CDR-L3 amino acid sequence of SEQ ID NO:80); R568-2E1 (having a CDR-H1 amino acid sequence of SEQ ID NO: 81, a CDR-H2 amino acid sequence of SEQ ID NO: 82, a CDR-H3 amino acid sequence of SEQ ID NO: 83, a CDR-L1 amino acid sequence of SEQ ID NO: 84, a CDR-L2 amino acid sequence of SEQ ID NO: 85, and a CDR-L3 amino acid sequence of SEQ ID NO: 86); R568-1G9 (having a CDR-H1 amino acid sequence of SEQ ID NO:87, a CDR-H2 amino acid sequence of SEQ ID NO:88, a CDR-H3 amino acid sequence of SEQ ID NO:89, a CDR-L1 amino acid sequence of SEQ ID NO:90, a CDR-L2 amino acid sequence of SEQ ID NO:91, and a CDR-L3 amino acid sequence of SEQ ID NO:92); R121-1F1 (having a CDR-H1 amino acid sequence of SEQ ID NO:93, a CDR-H2 amino acid sequence of SEQ ID NO:94, a CDR-H3 amino acid sequence of SEQ ID NO:95, a CDR-L1 amino acid sequence of SEQ ID NO:96, a CDR-L2 amino acid sequence of SEQ ID NO:97, and a CDR-L3 amino acid sequence of SEQ ID NO:98); R259-1B9 (having a CDR-H1 amino acid sequence of SEQ ID NO:99, a CDR-H2 amino acid sequence of SEQ ID NO:100, a CDR-H3 amino acid sequence of SEQ ID NO:101, a CDR-L1 amino acid sequence of SEQ ID NO:102, a CDR-L2 amino acid sequence of SEQ ID NO:103, and a CDR-L3 amino acid sequence of SEQ ID NO:104) An antibody or antigen-binding fragment thereof comprising a combination of heavy chain CDR1-CDR3 and light chain CDR1-CDR3 amino acid sequences of one antibody selected from the group consisting of:
2. R200-1B9 (having a variable region heavy chain amino acid sequence of SEQ ID NO:1 and a variable region light chain amino acid sequence of SEQ ID NO:2); R207-2F11 (having a variable region heavy chain amino acid sequence of SEQ ID NO:3 and a variable region light chain amino acid sequence of SEQ ID NO:4); R40-1G8 (having a variable region heavy chain amino acid sequence of SEQ ID NO:5 and a variable region light chain amino acid sequence of SEQ ID NO:6); R568-2G5 (having a variable region heavy chain amino acid sequence of SEQ ID NO:7 and a variable region light chain amino acid sequence of SEQ ID NO:8); R568-2B11 (having a variable region heavy chain amino acid sequence of SEQ ID NO:9 and a variable region light chain amino acid sequence of SEQ ID NO:10); R207-2G4 (having a variable region heavy chain amino acid sequence of SEQ ID NO: 11 and a variable region light chain amino acid sequence of SEQ ID NO: 12); R40-1C8 (having a variable region heavy chain amino acid sequence of SEQ ID NO: 13 and a variable region light chain amino acid sequence of SEQ ID NO: 14); R568-2B9 (having a variable region heavy chain amino acid sequence of SEQ ID NO: 15 and a variable region light chain amino acid sequence of SEQ ID NO: 16); R568-1B3 (having a variable region heavy chain amino acid sequence of SEQ ID NO: 17 and a variable region light chain amino acid sequence of SEQ ID NO: 18); R568-2E1 (having a variable region heavy chain amino acid sequence of SEQ ID NO: 19 and a variable region light chain amino acid sequence of SEQ ID NO: 20); R568-1G9 (having a variable region heavy chain amino acid sequence of SEQ ID NO:21 and a variable region light chain amino acid sequence of SEQ ID NO:22); R121-1F1 (having a variable region heavy chain amino acid sequence of SEQ ID NO:23 and a variable region light chain amino acid sequence of SEQ ID NO:24); R259-1B9 (having a variable region heavy chain amino acid sequence of SEQ ID NO:25 and a variable region light chain amino acid sequence of SEQ ID NO:26) 2. The antibody or antigen-binding fragment thereof according to claim 1, comprising a combination of a variable region heavy chain amino acid sequence and a variable region light chain amino acid sequence of an antibody selected from the group consisting of:
3. 3. The antibody or antigen-binding fragment thereof according to claim 1 or 2, wherein the amino acid sequence is that of one antibody selected from the group comprising R200-1B9, R207-2F11, R40-1G8, R568-2G5, R568-2B11, R207-2G4, R40-1C8, R568-2B9, and R568-1B3, preferably one antibody from the group comprising R200-1B9, R207-2F11, R40-1G8, and R568-2G5.
4. The antibody or antigen-binding fragment thereof of any one of claims 1 to 3, wherein the SARS-associated coronavirus strain is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
5. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, wherein the amino acid sequences of the CDRs or the variable regions contained therein are derived from an antibody capable of neutralizing each of SARS-CoV-2 strains B.1, B.1.1.7, B.1.351, B.1.429, B.1.617 and B.1.617.2 in a pseudovirus neutralization assay as described in the description with an IC50 of at most 0.4 μg / ml, preferably at most 0.1 μg / ml, more preferably at most 0.05 μg / ml, even more preferably at most 0.025 μg / ml, even more preferably at most 0.01 μg / ml, even more preferably at most 0.0025 μg / ml, particularly preferably at most 0.0015 μg / ml.
6. 6. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, wherein the amino acid sequences of the CDRs or the variable regions contained therein are derived from an antibody capable of neutralizing each of the SARS-CoV-2 spike escape mutants 69-70del, K417E, N439K, K444Q, V445A, G446V, L452R, Y453F, L455F, G476S, S477N, E484K, F486V, F490S, Q493R, Q493K, S494P, N501Y in a pseudovirus neutralization assay as described in the description with an IC50 of at most 1.3 μg / ml, preferably at most 0.5 μg / ml, more preferably at most 0.05 μg / ml, even more preferably at most 0.02 μg / ml, particularly preferably at most 0.01 μg / ml.
7. The antibody or antigen-binding fragment thereof of any one of claims 1 to 6, wherein the amino acid sequence of the CDRs or the variable region contained in the antibody or antigen-binding fragment thereof is obtained from an antibody capable of neutralizing each of the emerging SARS-CoV-2 spike escape mutants R346S, Q414H, N440K, and T478K in a pseudovirus neutralization assay described in the description with an IC50 of at most 0.0015 μg / ml.
8. The amino acid sequences of said CDRs or of said variable regions contained therein neutralize SARS-CoV-2 variants Wu-01, B. 1, B. 1.1.7, B. 1.351, B. 1.429, B. 1.617 and B. 1.81 in the pseudovirus neutralization assay described in the description across all variants and mutants with an average IC50 of at most 0.08 μg / ml, preferably at most 0.025 μg / ml, more preferably at most 0.01 μg / ml, even more preferably at most 0.006 μg / ml, particularly preferably at most 0.002 μg / ml.
8. The antibody or antigen-binding fragment thereof of any one of claims 1 to 7, which is derived from an antibody capable of neutralizing SARS-CoV-2, ...
9. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof according to any one of claims 1 to 8 and at least one pharma- ceutically acceptable excipient, preferably a vaccine composition for a human subject.
10. A kit comprising an antibody or antigen-binding fragment thereof according to any one of claims 1 to 8 and a container.
11. 11. An antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, a pharmaceutical composition according to claim 9, or a kit according to claim 10, for use as a medicament.
12. 11. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, the pharmaceutical composition according to claim 9, or the kit according to claim 10 for use as a vaccine.
13. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, the pharmaceutical composition according to claim 9, or the kit according to claim 10, for use in the treatment or prevention of a disease caused by a SARS-associated coronavirus in a human subject, preferably for use in the treatment or prevention of a disease caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in a human subject.
14. The antibody or antigen-binding fragment thereof of any one of claims 1 to 8, the pharmaceutical composition of claim 9, or the kit of claim 10, for use in preventing infection of a human subject with a SARS-associated coronavirus, preferably with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
15. 15. The antibody or antigen-binding fragment thereof for use according to any one of claims 11 to 14, wherein the antibody or antigen-binding fragment thereof is administered by intravenous infusion, inhalation application, subcutaneous injection or intramuscular injection, preferably the antibody or antigen-binding fragment thereof is administered in an absolute dose of up to 4000 mg, preferably up to 2400 mg, more preferably up to 1200 mg, even more preferably up to 600 mg, even more preferably up to 300 mg, particularly preferably up to 150 mg.
16. A nucleic acid encoding an antibody or antigen-binding fragment thereof according to any one of claims 1 to 8.
17. 17. An expression vector comprising the nucleic acid of claim 16 in operative association with an expression control sequence.
18. 18. A host cell comprising the nucleic acid of claim 16 or the expression vector of claim 17.
19. (a) culturing the host cell of claim 18 under conditions that allow expression of the antibody or antigen-binding fragment thereof; (b) recovering the antibody or antigen-binding fragment thereof; A method for producing an antibody or an antigen-binding fragment thereof according to any one of claims 1 to 8, comprising:
20. 9. The antibody of any one of claims 1 to 8 for use in a medicament in combination with at least one further antibody against SARS-associated coronavirus 2 (SARS-CoV-2), wherein said further antibody has a different binding specificity.
